Le conseil d'administration de Bitmine annonce le versement des premiers dividendes en espèces sur les actions privilégiées perpétuelles de série A à 9,50 % de la société L'admission à la cote de la Bourse de New York des actions privilégiées de série A a été approuvée sous le mnémo BMNP ; leur négociation devrait débuter le mardi 16 juin 2026 , /PRNewswire/ -- (NYSE : BMNR) Bitmine Immersion Technologies, Inc. (« Bitmine » ou la « société ») annonce aujourd'hui que son conseil d'administration a déclaré le premier dividende en espèces sur les actions privilégiées perpétuelles de série A à 9,50 % de la société (CUSIP : 09175D 200) (les « actions privilégiées de série A »).
Le dividende initial, qui correspond aux dividendes ordinaires cumulés depuis la date d'émission initiale du 10 juin 2026, sera payable en espèces conformément aux dispositions du certificat de désignation régissant les actions privilégiées de série A. Le premier dividende, d'un montant de 0,316667 $ par action, sera versé le 22 juin 2026 aux détenteurs des actions privilégiées de série A inscrits au registre des actionnaires à la clôture des marchés le 12 juin 2026.
La société a par ailleurs annoncé que le conseil d'administration avait également déclaré le deuxième dividende hebdomadaire en espèces de 0,105556 $ par action sur les actions privilégiées de série A, qui sera versé le 26 juin 2026 aux détenteurs inscrits des actions privilégiées de série A à la clôture des marchés le 16 juin 2026.
La société a également annoncé que l'admission à la cote de la Bourse de New York des actions privilégiées de série A avait été approuvée et que leur cotation débuterait le mardi 16 juin 2026 sous le mnémo « BMNP ». Equiniti Trust Company, LLC agit en tant qu'agent de transfert, agent de tenue de registre et agent payeur pour les actions privilégiées de série A.
À propos de Bitmine
Bitmine (NYSE : BMNR) est une société de minage de Bitcoin opérant aux États-Unis. L'entreprise déploie son capital excédentaire pour devenir la première société de trésorerie Ethereum au monde, mettant en œuvre une stratégie d'actifs numériques innovante pour les investisseurs institutionnels et les acteurs du marché public. Guidée par sa philosophie de « l'Alchimie des 5 % », l'entreprise s'est engagée à faire de l'ETH son principal actif de réserve de trésorerie, s'appuyant sur des activités natives au niveau du protocole, y compris le staking et des mécanismes de financement décentralisés. L'entreprise a lancé MAVAN (Made-in America VAlidator Network), une infrastructure de staking dédiée aux actifs de Bitmine, en 2026.
Pour en savoir plus, rendez-vous sur X :
https://x.com/bitmnr
https://x.com/fundstrat
Déclarations prospectives
Le présent communiqué de presse contient des déclarations qui constituent des déclarations prospectives au sens du Private Securities Litigation Reform Act de 1995. Les déclarations contenues dans le présent communiqué de presse qui ne sont pas purement historiques sont des déclarations prospectives qui impliquent des risques et des incertitudes. Ces déclarations prospectives peuvent être identifiées par des termes tels que « s'attendre à », « projeter », « avoir l'intention de », « croire », « anticiper », « estimer » et d'autres expressions similaires. Le présent document contient notamment des déclarations prospectives concernant le versement de dividendes par la société sur les actions privilégiées de série A, la cotation et le début des négociations de ces actions à la Bourse de New York, ainsi que la stratégie d'accumulation d'actifs numériques et les opérations de staking de la société. Pour évaluer ces déclarations prospectives, vous devez tenir compte de divers facteurs, notamment : la capacité de Bitmine à financer ses activités actuelles, ses opérations de trésorerie liées à l'Ethereum et ses projets d'activités futures ; les conditions de marché influant sur le cours des actions ordinaires et des actions privilégiées de série A de la société ; les évolutions réglementaires concernant les actifs numériques, y compris l'adoption et la mise en œuvre définitives des projets de loi en cours et des initiatives de la SEC ; la volatilité et l'imprévisibilité des prix des actifs numériques ; les performances, la fiabilité et la sécurité des opérations de staking de la société ; et la valeur future du Bitcoin et de l'Ethereum. Les performances et résultats réels futurs peuvent différer de manière significative de ceux exprimés dans les déclarations prospectives. Les déclarations prospectives sont soumises à de nombreuses conditions, dont beaucoup sont hors du contrôle de Bitmine, y compris celles énoncées dans la section « Risk Factors » du formulaire 10-K déposé par Bitmine auprès de la SEC le 21 novembre 2025, ainsi que dans tous les autres documents déposés auprès de la SEC, tels que modifiés ou mis à jour de temps à autre. Des copies des documents déposés par Bitmine auprès de la SEC sont disponibles sur son site web à l'adresse suivante : www.sec.gov. Bitmine ne s'engage pas à mettre à jour ces déclarations pour tenir compte des révisions ou changements intervenus après la date de ce communiqué, sauf si la loi l'exige.
Der Vorstand von Bitmine beschließt die erste Bardividendenausschüttung auf die 9,50 %-Vorzugsaktien der Serie A des Unternehmens Die Notierung der Vorzugsaktien der Serie A an der New York Stock Exchange unter dem Symbol „BMNP" wurde genehmigt; der Handelsbeginn ist für Dienstag, den 16. Juni 2026, vorgesehen , /PRNewswire/ -- (NYSE: BMNR) Bitmine Immersion Technologies, Inc. („Bitmine" oder das „Unternehmen") gab heute bekannt, dass sein Vorstand die erste Bardividende auf die 9,50 %-igen unbefristeten Vorzugsaktien der Serie A des Unternehmens (CUSIP: 09175D 200) (die „-Vorzugsaktien der Serie A") beschlossen hat.
Die Erstdividende, die sich aus den seit dem Erstausgabedatum am 10. Juni 2026 angefallenen regulären Dividenden zusammensetzt, wird gemäß den Bestimmungen der Emissionsbedingungen für die Vorzugsaktien der Serie A in bar ausgezahlt. Die erste Dividende in Höhe von 0,316667 USD pro Aktie wird am 22. Juni 2026 an die zum Geschäftsschluss am 12. Juni 2026 eingetragenen Inhaber der Vorzugsaktien der Serie A ausgezahlt.
Das Unternehmen gab ferner bekannt, dass der Vorstand zudem die zweite wöchentliche Bardividende in Höhe von 0,105556 USD pro Aktie auf die Vorzugsaktien der Serie A beschlossen hat, die am 26. Juni 2026 an die zum Geschäftsschluss am 16. Juni 2026 eingetragenen Inhaber der Vorzugsaktien der Serie A ausgezahlt wird.
Das Unternehmen gab außerdem bekannt, dass die Notierung der Vorzugsaktien der Serie A an der New York Stock Exchange genehmigt wurde und der Handel am Dienstag, dem 16. Juni 2026, unter dem Tickersymbol „BMNP" beginnen wird. Die Equiniti Trust Company, LLC fungiert als Transferstelle, Registerführer und Zahlstelle für die Vorzugsaktien der Serie A.
Informationen zu Bitmine
Bitmine (NYSE: BMNR) ist ein Bitcoin-Miner mit Aktivitäten in den USA. Das Unternehmen setzt sein überschüssiges Kapital ein, um das weltweit führende Ethereum-Treasury-Unternehmen zu werden und eine innovative Strategie für digitale Vermögenswerte für institutionelle Investoren und öffentliche Marktteilnehmer umzusetzen. Geleitet von seiner Philosophie der „Alchemy of 5 %" setzt das Unternehmen auf ETH als primären Treasury-Reservewert und nutzt dabei native Aktivitäten auf Protokollebene, darunter Staking und dezentrale Finanzmechanismen. Das Unternehmen führte im Jahr 2026 MAVAN (Made-in America VAlidator Network) ein, eine spezielle Staking-Infrastruktur für Bitmine-Vermögenswerte.
Weitere Einzelheiten finden Sie auf X:
https://x.com/bitmnr
https://x.com/fundstrat
Zukunftsgerichtete Aussagen
Diese Pressemitteilung enthält Aussagen, die „zukunftsgerichtete Aussagen" im Sinne des Private Securities Litigation Reform Act von 1995 sind. Die Aussagen in dieser Pressemitteilung, die nicht rein historischer Natur sind, sind zukunftsgerichtete Aussagen, die Risiken und Unsicherheiten beinhalten. Diese zukunftsgerichteten Aussagen sind an Begriffen wie „erwartet", „prognostiziert", „prognostiziert", „beabsichtigt", „glaubt", „geht davon aus", „schätzt" und ähnlichen Formulierungen zu erkennen. Dieses Dokument enthält insbesondere zukunftsgerichtete Aussagen hinsichtlich der Dividendenzahlungen des Unternehmens auf die Vorzugsaktien der Serie A, der Notierung und der Aufnahme des Handels mit den Vorzugsaktien der Serie A an der New York Stock Exchange sowie der Strategie des Unternehmens zum Aufbau digitaler Vermögenswerte und seiner Staking-Aktivitäten. Bei der Bewertung dieser zukunftsgerichteten Aussagen sollten Sie verschiedene Faktoren berücksichtigen, darunter: die Fähigkeit von Bitmine, sein laufendes Geschäft, die Treasury-Aktivitäten im Zusammenhang mit Ethereum sowie geplante zukünftige Geschäftsvorhaben zu finanzieren; Marktbedingungen, die den Handelspreis der Stammaktien und der Vorzugsaktien der Serie A des Unternehmens beeinflussen; regulatorische Entwicklungen im Bereich digitaler Vermögenswerte, einschließlich der endgültigen Verabschiedung und Umsetzung anhängiger Gesetzgebungsvorhaben und Initiativen der SEC; die Volatilität und Unvorhersehbarkeit der Preise digitaler Vermögenswerte; die Leistung, Zuverlässigkeit und Sicherheit der Staking-Aktivitäten des Unternehmens; sowie der zukünftige Wert von Bitcoin und Ethereum. Die tatsächlichen künftigen Entwicklungen und Ergebnisse können wesentlich von den in zukunftsgerichteten Aussagen ausgedrückten Ergebnissen abweichen. Zukunftsgerichtete Aussagen unterliegen zahlreichen Bedingungen, von denen viele außerhalb der Kontrolle von Bitmine liegen, einschließlich derjenigen, die im Abschnitt „Risikofaktoren" des Formulars 10-K von Bitmine aufgeführt sind, das am 21. November 2025 bei der SEC eingereicht wurde, sowie allen anderen bei der SEC eingereichten Unterlagen, die von Zeit zu Zeit geändert oder aktualisiert werden. Kopien der von Bitmine bei der SEC eingereichten Unterlagen sind auf der Website der SEC, www.sec.gov, verfügbar. Bitmine übernimmt keine Verpflichtung, diese Aussagen bei Überarbeitungen oder Änderungen nach dem Datum dieser Mitteilung zu aktualisieren, es sei denn, dies ist gesetzlich vorgeschrieben.
As told to You're currently following this author! Want to unfollow? Unsubscribe via the link in your email.
Josh Giegel worked at SpaceX from 2009 to 2012. He's now the CEO of Gambit. Josh Giegel This as-told-to essay is based on a conversation with Josh Giegel, the 41-year-old cofounder of the AI startup Gambit, who lives in Los Angeles. It's been edited for length and clarity.
I was in grad school at Stanford, finishing my master's and wanting to do a Ph.D.
I had worked at NASA the previous summer, and one of the women I worked with was also a Stanford graduate, and was like: "You're going to be so bored at NASA. Why don't you check out this small space company in Los Angeles called SpaceX?"
I applied and interviewed in the two weeks between flight three and flight four of Falcon 1. I interviewed with Elon; he was still interviewing pretty much everyone at the time. I remember going back to my advisor and saying, "There's nothing I'd rather do on the planet than what he just described."
My Master's ended at the end of 2008, and I began in 2009.
I was on what's called the propulsion analysis team, which was four or five people. Our responsibility was: How do you design the first reusable rocket engine? A very small group of us was responsible for the initial stuff that was on Falcon 9.
A SpaceX Falcon 9 rocket carrying a payload into space. Paul Hennesy/Anadolu via Getty Images I started there when I was 23, and I left when I was 27. It was a little bit of naive immaturity. I knew I wanted to start a company one day, and SpaceX was growing like crazy. I wanted to be on a founding team. I still love the company; I almost went back two or three years later before I ended up starting a company of my own.
The IPO is pretty cool. I'm on a bunch of text threads with guys who were there around the same time, and a couple of them are still there. It's cool to see just how big it became.
When I got there, and they gave the offer, there was an equity component. I remember the HR woman who was going over it with me saying, "We think some day, in 10 or 15 years, this might be worth $250,000-300,000." I distinctly remember her saying, "It might get you a nice down payment on a house in Los Angeles."
We all laugh about it now. But, at the time, the saying was: the fastest way to become a millionaire in space is to start as a billionaire.
Buybacks have been really regular for the last 10 years. Every now and then, we'd take a little bit out. For example, we paid off my wife's student loans a number of years ago. We put down a down payment on a house.
I joke: We did actually get a down payment on a house! She wasn't lying when she said that. It's a house that, on our normal salaries at startups, we wouldn't have been able to afford without that additional windfall.
We also love traveling. We've got a seven-year-old and a one-year-old. We're going to go on slightly more adventurous trips because of it.
My wife is also thinking of doing a larger career change that would come with a decent salary reduction, which she probably wouldn't have been able to do without something like SpaceX.
Professionally, I've always been risky. If the majority of your net worth is tied up in a rocket company, you must be a risk-tolerant individual.
Gambit is a VC-backed company. We've raised about $15 million to date, and there are a couple more investment rounds that are coming. The IPO puts you in a position where folks with a substantial amount of equity could be interested in becoming investors.
At least ten of the people I worked with intimately have started their own company. There was a band that I played in with five SpaceX people; four of us started our own companies. I played guitar.
That whole ecosystem can fund its own endeavors and each other. The quantum of capital that they can put in is not like your typical family and friends round. That's typically $20,000, $50,000, maybe $100,000. Here, that could be on the order of $1 million, maybe $2 million per check.
You also become a bit of a mercenary, asking, "I don't need a paycheck from what I'm going to go do, so what am I going to go do?" It's liberating.
The equity also allows me to take a lower salary at my startup, so that I can go out and hire more people to make my company more successful.
Read next
Henry Chandonnet You're currently following this author! Want to unfollow? Unsubscribe via the link in your email.
as told to SpaceX Startups More Student Loans Real Estate Elon Musk
Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.
SummaryMeta Platforms remains under pressure due to investor skepticism over rising AI-driven capex and potential equity dilution.META’s AI investments are already driving accelerating ad revenue growth, with Q1 FY26 revenue up 33% YoY and both ad impressions and pricing rising.Custom silicon deployment and new revenue streams like Business Agent, Meta One, and AI glasses offer significant long-term revenue and margin potential for the company.Trading at a forward P/E of 17x and with a 45%+ upside to consensus price targets, META presents a highly attractive risk-reward and I reiterate my buy rating.Looking for a portfolio of ideas like this one? Members of The REIT Forum get exclusive access to our subscriber-only portfolios. Learn More »Sitewide Sale 2026: Get 20% Off J Studios/DigitalVision via Getty Images
Introduction & Investment Thesis Meta (META) continues to remain under pressure. It is currently the second-worst-performing hyperscaler on a YTD basis, as investors have not come to terms with the company’s capex plans.
In
6.95K Followers
Analyst’s Disclosure: I/we have a beneficial long position in the shares of META, AMZN, AMD either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.
This year is set to be the biggest year for initial public offerings (IPOs) in history. We've already seen a handful of big offerings so far, most notably Space Exploration Technologies, known as SpaceX, which came to market at a $1.77 trillion valuation. But that could be just the first of three mega-artificial intelligence (AI) companies making their market debuts this year.
One of those was OpenAI, which took the first steps toward its IPO, confidentially filing its registration statements with the Securities and Exchange Commission on June 8. But the company warned that the actual IPO date could sometime well in the future. "We have not decided on timing yet; it may be a while because there are things we want to do that are likely easier as a private company," the company said in a blog post announcing the filing.
But investors looking to gain exposure to the leading AI lab don't have to wait for the IPO. There are several options to add it to your portfolio today.
Image source: Getty Images.
Invest in its largest outside shareholder When OpenAI transitioned from a nonprofit to a capped-profit company in 2019, Microsoft (MSFT +0.11%) became an early investor in the for-profit subsidiary with a $1 billion commitment. It also integrated OpenAI's services into Microsoft's cloud computing platform, Azure.
Microsoft has since added $12 billion more to its investment. After OpenAI underwent further corporate restructuring, Microsoft now holds a 27% stake in the business. Although an IPO will dilute that stake somewhat, it's poised to remain the largest outside shareholder.
At a market value of about $910 billion based on private market transactions, that means Microsoft's stake is currently worth about $245 billion. That's about 8.5% of the company's total market cap as of this writing.
Today's Change
(
0.11
%) $
0.42
Current Price
$
390.76
Microsoft will also benefit from a revenue share agreement through 2030. Microsoft receives 20% of OpenAI's revenue, up to $38 billion total. As part of the agreement, Microsoft no longer pays OpenAI for using its intellectual property. That provides further exposure to OpenAI's results over the medium term.
On top of that, OpenAI has committed to spending $250 billion on Azure services through 2032. That gives Microsoft the confidence to invest heavily in building out compute capacity to meet demand for Azure.
OpenAI is just a piece of Microsoft's total backlog of remaining performance obligations, which reached $627 billion last quarter. So the overall expected return on invested capital remains strong for the cloud computing business.
Although Microsoft offers much more than just exposure to OpenAI's economics, it's one of the best ways to invest in OpenAI's future success, along with one of its biggest partners.
Invest in a fund that holds the stock already Multiple closed-end funds hold OpenAI shares in their portfolios, but for investors who want as much exposure to OpenAI as possible, one of the best options is Robinhood's Robinhood Venture Fund I (RVI 3.03%).
The fund opened in March, focusing primarily on AI and fintech companies. The largest holding in its first quarterly disclosure was Databricks, with a net asset value of $82 million, or about 12.5% of the fund's total value. However, the investment manager added $75 million worth of OpenAI in April, putting it on a roughly equal footing with the Databricks investment.
Today's Change
(
-3.03
%) $
-1.10
Current Price
$
35.25
There are a few important considerations before investing in the Robinhood fund. First, it's common for closed-end funds to trade below their net asset value due to concerns about liquidation. That could result in increased volatility in the fund's share price, on top of the inherently volatile investments it holds.
The second consideration is the expense ratio. Investors will pay 3.13% of assets under management. Robinhood is offering a reduced management fee as an introductory rate through Aug. 27, bringing the total fee down to 2.13%.
Despite those concerns, the fund offers a concentrated way to gain exposure to OpenAI and several other high-profile private companies in the AI and fintech sector. It could be worth a small position for some investors.
La donación a Boys & Girls Clubs of America respaldará programas de fútbol, el desarrollo de la fuerza laboral y otras iniciativas dirigidas a la juventud del sur de California
, /PRNewswire-HISPANIC PR WIRE/ -- Mientras la Selección Nacional Masculina de EE. UU. inicia su camino en la Copa Mundial de la FIFA 26™ en Los Ángeles, The Home Depot celebra el momento con una donación de $250,000 para apoyar a Boys & Girls Clubs of America en toda la región metropolitana de Los Ángeles.
La inversión respaldará una variedad de iniciativas dirigidas a la juventud local, que incluyen programas de fútbol, oportunidades de desarrollo laboral y otros programas comunitarios de los clubes en todo el sur de California.
Como socio estratégico de U.S. Soccer y promotor del crecimiento continuo de este deporte en Estados Unidos, The Home Depot ayuda a generar mayor acceso y oportunidades para la próxima generación de jugadores, aficionados y comunidades vinculadas al juego.
"Con los ojos del mundo puestos en el debut de la Selección Nacional Masculina de EE. UU. en la Copa Mundial en Los Ángeles, nos enorgullece invertir en las comunidades que le dan tanto significado a este deporte", afirmó Allison Kolber, vicepresidenta de Marketing Integrado de The Home Depot. "Esta donación tiene como finalidad ayudar a que los jóvenes de la zona metropolitana de Los Ángeles accedan a oportunidades, generen vínculos y formen parte de la emoción que rodea a este momento histórico para el fútbol en Norteamérica".
La iniciativa refleja el firme compromiso de The Home Depot con el apoyo a las comunidades vinculadas al torneo y con la celebración del impacto positivo que el fútbol puede generar tanto dentro como fuera de la cancha.
"Nos enorgullece trabajar con excelentes socios como The Home Depot, quienes comparten nuestra convicción de que todos, en cualquier lugar, deben sentir que tienen un lugar en el fútbol. Mediante la expansión del juego, la ampliación del acceso y el aprovechamiento del fútbol como una fuerza impulsora del bienestar, podemos asegurar que el legado de este momento histórico llegue a las comunidades de toda la zona metropolitana de Los Ángeles e inspire a las próximas generaciones durante los años venideros", señaló Lex Chalat, directora ejecutiva de Soccer Forward Foundation, el brazo de impacto social de U.S. Soccer.
"A medida que crece la emoción en torno al deporte, esta inversión ayudará a que más jóvenes se beneficien de las actividades deportivas en sus comunidades", afirmó Chad Hartman, vicepresidente nacional de Alianzas Corporativas y Participación de Boys & Girls Clubs of America. "Nos enorgullece colaborar con The Home Depot para ampliar el acceso al fútbol, al tiempo que respaldamos la preparación laboral y las iniciativas de desarrollo juvenil que ayudan a los jóvenes a desarrollar confianza, adquirir habilidades para la vida y alcanzar su máximo potencial".
El contenido relacionado con la donación y la iniciativa comunitaria se difundirá en los canales propios y de redes sociales a lo largo de todo el torneo, y se planifican programas adicionales para este verano.
Acerca de The Home Depot
The Home Depot es la cadena minorista especializada en mejoras del hogar más grande del mundo. Al cierre del primer trimestre del año fiscal 2026, la empresa operaba un total de 2,361 tiendas minoristas y más de 1,280 establecimientos SRS en los 50 estados, el Distrito de Columbia, Puerto Rico, las Islas Vírgenes de EE. UU., Guam, 10 provincias canadienses y México. La empresa tiene contratados aproximadamente 470,000 empleados. Las acciones de The Home Depot se cotizan en la bolsa de valores de Nueva York (NYSE: HD) y se incluyen en el Promedio Industrial Dow Jones y el índice Standard & Poor's 500.
ACERCA DE BOYS & GIRLS CLUBS OF AMERICA
Durante más de 160 años, Boys & Girls Clubs of America (BGCA.org) ha brindado un lugar seguro para que niños y adolescentes aprendan y se desarrollen. Los Clubes ofrecen mentores adultos considerados, diversión y amistad, y programas de desarrollo juvenil de alto impacto a diario durante las horas críticas no lectivas. El programa de Boys & Girls Clubs promueve el éxito académico, el buen carácter, el liderazgo y el estilo de vida saludable. Más de 5,500 Clubes atienden a más de 4 millones de jóvenes mediante la afiliación a los Clubes y la ayuda a la comunidad. Los Clubes se encuentran en ciudades, pueblos, viviendas públicas y tierras indígenas de todo el país y atienden a familias de militares en centros juveniles afiliados a la BGCA en instalaciones militares estadounidenses de todo el mundo. La sede central nacional se encuentra en Atlanta. Más información acerca de Boys & Girls Clubs of America en Facebook y LinkedIn.
ACERCA DE U.S. SOCCER
Fundada en 1913, U.S. Soccer, una organización sin fines de lucro 501(c)(3), es el organismo rector oficial de este deporte en Estados Unidos. Nuestra visión es clara: existimos para servir al fútbol. Nuestra ambición consiste en encender una pasión nacional por el juego y realzar su poder para unir, inspirar y dignificar. Creemos que el fútbol es más que un deporte, es una fuerza impulsora del bienestar. Nos enfocamos en tres pilares: U.S. Soccer Everywhere (U.S. Soccer en todas partes), para hacer del fútbol el deporte número uno en práctica dentro de cada comunidad de Estados Unidos; U.S. Soccer is Yours (U.S. Soccer es de ustedes), para garantizar que todos sientan que el futuro del fútbol en EE. UU. les pertenece; y U.S. Soccer Success (Éxito de U.S. Soccer), para ganar torneos importantes, incluidas las Copas Mundiales. Juntos, nos corresponde a nosotros construir el futuro de este deporte. Para más información, visite ussoccer.com/ourvision.
ACERCA DE SOCCER FORWARD
La Soccer Forward Foundation es un motor clave en la visión integral de U.S. Soccer de que el fútbol es una fuerza impulsora del bienestar. Con la convicción de que el fútbol contribuye a tener comunidades más saludables, conectadas y equitativas, Soccer Forward respalda los esfuerzos de U.S. Soccer para ampliar el acceso a este deporte y ayuda a que el juego llegue a más personas y genere un cambio duradero. Soccer Forward se enfoca en habilitar y equipar a personas, lugares y programas para hacer que el deporte llegue a más comunidades en todo Estados Unidos, así como en aportar investigaciones, capacitaciones y pautas de vanguardia para demostrar la contribución del fútbol en los resultados de salud de las comunidades. Además, definirá estándares y ofrecerá apoyo comercial y técnico para desarrollar el ecosistema del fútbol femenino en todo Estados Unidos y a nivel mundial. Para más información, visite ussoccer.com/soccer-forward.
Oracle (NYSE: ORCL) will pay its next quarterly dividend on July 24, 2026, with shareholders set to receive $0.50 per share.
As a result, investors holding 100 ORCL shares will collect $50 from the upcoming payment before taxes.
The software and cloud computing giant declared the dividend with an ex-dividend date of July 10, 2026.
The payout remains unchanged from the previous quarter, bringing Oracle’s annual dividend to $2 per share and yielding approximately 1.09% at its current share price.
At the current payout rate, investors holding 100 shares would generate $200 in annual dividend income.
Oracle has maintained a relatively modest dividend yield throughout its expansion, reflecting management’s focus on reinvesting capital into growth initiatives rather than prioritizing larger cash distributions.
The dividend payment comes during a volatile period for Oracle stock. Shares closed at $184 on June 12, down roughly 15% from levels above $200 reached earlier in the week following the company’s latest earnings report.
ORCL stock dividend details. Source: Dividend.com Oracle fundamentals While Oracle delivered strong fiscal 2026 results, investors focused on the scale of planned AI-related spending and the potential impact on margins, cash flow, and debt levels.
Oracle reported fiscal 2026 revenue of $67.4 billion, up 17% year over year, while cloud revenue surged 39% to $34 billion. Demand for Oracle Cloud Infrastructure continued to accelerate, helping the company build a record remaining performance obligation (RPO) backlog of $638 billion.
The backlog increased by approximately $85 billion from the previous quarter and provides significant visibility into future revenue growth.
Much of the contracted business is tied to large multi-year cloud and artificial intelligence agreements that are expected to support Oracle’s expansion over the coming years.
Despite those strong fundamentals, concerns about rising debt levels, margin pressure, and elevated AI infrastructure spending weighed on investor sentiment and pushed the stock lower in the days following earnings.
Best Crypto Exchange for Intermediate Traders and Investors
Invest in cryptocurrencies and 3,000+ other assets including stocks and precious metals.
0% commission on stocks - buy in bulk or just a fraction from as little as $10. Other fees apply. For more information, visit etoro.com/trading/fees.
Copy top-performing traders in real time, automatically.
eToro USA is registered with FINRA for securities trading.
30+ million Users worldwide
Securities trading offered by eToro USA Securities, Inc. (“the BD”), member of FINRA and SIPC. Cryptocurrency offered by eToro USA LLC (“the MSB”) (NMLS: 1769299) and is not FDIC or SIPC insured. Investing involves risk, and content is provided for educational purposes only, does not imply a recommendation, and is not a guarantee of future performance. Finbold.com is not an affiliate and may be compensated if you access certain products or services offered by the MSB and/or the BD
Join Finbold's newsroom, become a Sales Executive today! Apply now to join Finbold as a crypto/finance news writer!
Oracle (NYSE: ORCL) will pay its next quarterly dividend on July 24, 2026, with shareholders set to receive $0.50 per share.
As a result, investors holding 100 ORCL shares will collect $50 from the upcoming payment before taxes.
The software and cloud computing giant declared the dividend with an ex-dividend date of July 10, 2026.
The payout remains unchanged from the previous quarter, bringing Oracle’s annual dividend to $2 per share and yielding approximately 1.09% at its current share price.
At the current payout rate, investors holding 100 shares would generate $200 in annual dividend income.
Oracle has maintained a relatively modest dividend yield throughout its expansion, reflecting management’s focus on reinvesting capital into growth initiatives rather than prioritizing larger cash distributions.
The dividend payment comes during a volatile period for Oracle stock. Shares closed at $184 on June 12, down roughly 15% from levels above $200 reached earlier in the week following the company’s latest earnings report.
ORCL stock dividend details. Source: Dividend.com Oracle fundamentals While Oracle delivered strong fiscal 2026 results, investors focused on the scale of planned AI-related spending and the potential impact on margins, cash flow, and debt levels.
Oracle reported fiscal 2026 revenue of $67.4 billion, up 17% year over year, while cloud revenue surged 39% to $34 billion. Demand for Oracle Cloud Infrastructure continued to accelerate, helping the company build a record remaining performance obligation (RPO) backlog of $638 billion.
The backlog increased by approximately $85 billion from the previous quarter and provides significant visibility into future revenue growth.
Much of the contracted business is tied to large multi-year cloud and artificial intelligence agreements that are expected to support Oracle’s expansion over the coming years.
Despite those strong fundamentals, concerns about rising debt levels, margin pressure, and elevated AI infrastructure spending weighed on investor sentiment and pushed the stock lower in the days following earnings.
Best Crypto Exchange for Intermediate Traders and Investors
Invest in cryptocurrencies and 3,000+ other assets including stocks and precious metals.
0% commission on stocks - buy in bulk or just a fraction from as little as $10. Other fees apply. For more information, visit etoro.com/trading/fees.
Copy top-performing traders in real time, automatically.
eToro USA is registered with FINRA for securities trading.
30+ million Users worldwide
Securities trading offered by eToro USA Securities, Inc. (“the BD”), member of FINRA and SIPC. Cryptocurrency offered by eToro USA LLC (“the MSB”) (NMLS: 1769299) and is not FDIC or SIPC insured. Investing involves risk, and content is provided for educational purposes only, does not imply a recommendation, and is not a guarantee of future performance. Finbold.com is not an affiliate and may be compensated if you access certain products or services offered by the MSB and/or the BD
Join Finbold's newsroom, become a Sales Executive today! Apply now to join Finbold as a crypto/finance news writer!
Companies have been making memory and storage solutions for decades, but it was artificial intelligence (AI) that recently woke up the sleepy sector. That's allowing specialized memory and storage providers like Micron Technology, Samsung Electronics, and SK Hynix to cash in.
Unfortunately for investors, owning those companies isn't the most straightforward. It costs nearly $1,000 to own a full share of Micron, while Samsung and SK Hynix are based in South Korea and do not offer American depository receipts (ADRs), making it more difficult for U.S. investors to own shares.
SK Hynix did recently file for a listing of ADRs on a U.S. exchange, but the exact timing of when shares could be listed is still unclear.
Nevertheless, there's a way to participate in the success of all three stocks immediately for less than $70: the Roundhill Memory ETF (DRAM 0.17%).
Image source: Getty Images.
The access DRAM provides The Roundhill Memory ETF launched on April 2 and, as of June 12, held 15 positions. Through total return swaps, which provide access to a stock through a derivative contract without ownership, and direct ownership, Micron is one of the top holdings in terms of portfolio weight of the exchange-traded fund (ETF).
Micron provides memory and storage solutions for personal computers, mobile phones, and the automotive industry, but shares have really taken off thanks to AI; the Micron stock price is up nearly 250% on the year. Micron offers a portfolio of data center memory solutions, which is helping drive record revenue. For the company's fiscal second quarter 2026 (ended Feb. 26), revenue for its core data center business unit was $5.6 billion, an increase of 211% from the $1.8 billion reported in the same period a year prior.
For Samsung, another top holding of the ETF, it also offers memory solutions like Micron. But unlike Micron, it focuses on more than just memory, providing a one-stop shop for logic, memory, foundry, and packing solutions. It recently launched samples of its high-bandwidth memory HBM4E chip, which companies like Nvidia and Alphabet need for AI accelerators. On the Korea Exchange (KRX), shares are up more than 150%.
Switching gears to SK Hynix, another significant holding in the RoundHill Memory ETF, it's more like Micron than Samsung in terms of purely focusing on advanced memory and storage offerings. In a big win for the company, it just landed a multi-year agreement with Nvidia to partner on AI memory chips. On the KRX, shares have jumped more than 200% for the year.
Today's Change
(
-0.17
%) $
-0.11
Current Price
$
65.01
The risks and rewards If the fervor for memory and storage stocks dies down, this ETF would be hit with losses particularly hard, as there's little room for it to hide. Just recently, shares dropped 17.7% from June 3 to June 10. That said, the memory and storage market is becoming less cyclical as AI creates constant demand, which creates a stronger backstop for memory and storage makers than they've had in the past.
Roundhill Memory holds some of the top memory and storage companies, offers access to Micron for less than $1,000, and gives U.S. investors a way to invest in SK Hynix and Samsung without dealing with international trading. As a small position in a well-rounded portfolio, the Roundhill Memory ETF can offer long-term upside for investors who can handle short-term volatility.
Nvidia (NVDA +0.15%) and Micron Technology (MU 1.02%) each have seen revenue soar amid this artificial intelligence (AI) boom. This is because these companies offer something that is crucial for the development and performance of this hot technology: compute power, and memory and storage.
Nvidia is the compute expert, designing the fastest graphics processing units (GPUs) around, while Micron offers the memory and storage necessary for AI tasks. Investors have recognized these companies' strengths and have rushed to get in on the stocks. As a result, Nvidia and Micron each have climbed more than 1,000% over the past five years.
Both of these companies are likely to win as this AI story continues to unfold. But if you could only invest in one today, which is the better AI growth buy? Let's find out.
Image source: Getty Images.
The case for Nvidia Nvidia is the leading designer of GPUs, the chips powering key AI tasks like the training and inference of AI models. Though rivals also offer compute, and in many cases are delivering revenue growth too, Nvidia remains a big step ahead. Companies may invest in a broad range of compute, but those who aim to win in AI generally rely at least partially on Nvidia's GPUs -- their high speed helps customers reach the finish line faster and may result in a lower total cost of ownership over time.
Today's Change
(
0.15
%) $
0.30
Current Price
$
205.18
But Nvidia doesn't rely on GPUs alone. The company offers a full portfolio of related products and services, and today it's in the process of entering another enormous market: the central processing unit (CPU) market. These are the chips that generally power all computers, and they are a key tool to fuel AI agents, the next area of AI growth. Nvidia is launching its first-ever stand-alone CPU this fall and is conquering the CPU for PC market with a new superchip. This may set it on track for leadership in this $200 billion market.
Nvidia also has designed products and services specifically for certain markets, from telecom to healthcare and robotics, which offers it a pretty significant revenue growth opportunity moving forward.
The case for Micron Micron, as mentioned, is an expert in memory and storage -- two critical elements for AI customers, particularly as the era of AI agents unfolds. AI agents go through a thought process and carry out steps, in many cases multiple steps, to solve a particular problem. For this, they clearly need compute power but also memory and storage.
Demand for these products has been so high that Micron recently reported records in revenue, gross margin, earnings per share, and free cash flow, and revenue from DRAM and NAND, two types of memory, increased in the triple digits.
"In the AI era, memory has become a strategic asset for our customers," the company said in the latest earnings update.
Today's Change
(
-1.02
%) $
-10.15
Current Price
$
985.72
Micron has noted increased adoption of AI agents in PCs and smartphones, a point that supports ongoing demand for the company's products.
The tech giant expects earnings records in the current quarter, the third fiscal quarter. Micron predicts free cash flow will "roughly double sequentially" in the period. And it forecasts third-quarter revenue of $33.5 billion, a record high for any quarter or year so far.
The biggest headwind for Micron at this point is supply -- due to supply constraints, it's unable to serve 100% of its customers' needs.
Which stock is the better buy? Though Nvidia and Micron both have climbed this year, Micron's advance is much steeper than that of Nvidia. It's soared more than 240%, while Nvidia has added 9% as of the June 11 market close.
Micron actually is cheaper than Nvidia: It trades for 16x forward earnings estimates, while Nvidia trades for 22x. But while Nvidia's valuation has fallen this year, Micron's has increased.
NVDA PE Ratio (Forward) data by YCharts
I think Micron is a great stock to own, but the run-up in its price and rising valuation suggest this player could be heading for a pullback at a certain point. Meanwhile, Nvidia, at today's valuation, offers investors a fantastic buying opportunity. And that's why, today, I think Nvidia is the better AI growth buy to add to a tech portfolio.
*Stock prices used were the afternoon prices of June 11, 2026. The video was published on June 13, 2026.
Parkev Tatevosian, CFA has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Broadcom. The Motley Fool has a disclosure policy. Parkev Tatevosian is an affiliate of The Motley Fool and may be compensated for promoting its services. If you choose to subscribe through his link, he will earn some extra money that supports his channel. His opinions remain his own and are unaffected by The Motley Fool.
SummaryChubb Limited offers consistent compounding, evidenced by market-beating returns and moderate value-at-risk.The company has a diverse revenue base, deriving from property and casualty insurance, smooth life and health premiums, general insurance, and reinsurance.Low overhead and acquisition costs allow for high margins, which are shared with investors. Moreover, a $136.9 billion investment portfolio assists with shortfall protection and diversified gains.The stock is currently in a momentum trend amid consistent profitability and positive animal spirits from investors. My strategy is to manage my position with a dollar-cost averaging equivalent.Risks include: Volatile results from reinsurance, market risk, black swan events, and FX translation. ridham supriyanto/iStock Editorial via Getty Images
This analysis discusses Chubb Limited (NYSE:CB), a diversified insurer that I recently added to my portfolio. Instead of emphasizing price discovery, I wanted to discuss Chubb from a strategic investment point of view, as I think
4.89K Followers
Analyst’s Disclosure: I/we have a beneficial long position in the shares of CB either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
Kindly note that our content on Seeking Alpha and other platforms doesn't constitute financial advice. Instead, we set the tone for a discussion panel among subscribers. As such, we encourage you to consult a registered financial advisor before committing capital to financial instruments.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.
The generative artificial intelligence (AI) revolution is in full force, with agentic AI now catapulting AI-related stocks to new heights.
Still, those who remember the internet boom and bust know that many darlings of that boom didn't become long-term winners. Some even went bankrupt. However, those who eventually emerged as winners of that boom became some of the world's biggest companies, making up most of today's "Magnificent Seven."
Today, the multitrillion-dollar question is, who will be the winner of the AI revolution? Well, Berkshire Hathaway's (BRKA +0.76%) (BRKB +0.71%) Greg Abel just made a big bet that one of the Magnificent Seven internet-era winners will also win the AI races -- and Berkshire's investment itself could help make that bet a reality.
Today's Change
(
0.53
%) $
1.90
Current Price
$
359.67
Berkshire triples down on Google In the first quarter -- Abel's first with total control over Berkshire's investment decisions -- Berkshire more than tripled its investment in Google parent Alphabet (GOOG +0.45%) (GOOGL +0.53%).
In addition to tripling down on Alphabet stock last quarter, Berkshire subsequently said it would buy another $10 billion worth of the $80 billion equity raise that Alphabet recently announced on June 1. That would equate to another 28.6 million shares, increasing Berkshire's stake by another 50%, barring any additional Alphabet purchases made since March 31.
As of this writing, Berkshire's combined 86.7 million shares (that we know about) would amount to about a $30.9 billion stake at today's share price. That would make Alphabet Berkshire's fourth-largest public equity holding, behind only Apple, American Express, and Coca-Cola.
Alphabet has survived, now primed to thrive in AI Back when Berkshire first established its position in Alphabet, I wrote that the likely reason was a reacceleration in Search-related paid clicks, which occurred in the second quarter of 2025 and was subsequently reported in the third quarter, when Berkshire took its initial position.
Alphabet was the cheapest of the Magnificent Seven stocks at that point due to fears that generative AI could disrupt Google Search, Alphabet's main cash cow. However, after Alphabet innovated and introduced features such as AI Overviews and AI Mode within the Search bar, paid clicks reaccelerated. That appeared to prove that the Search business wasn't going away, thanks to Alphabet's innovation.
However, Alphabet's stock has roughly doubled over the past year, and its valuation has risen accordingly. No longer is Alphabet the typical value investment that investors have come to expect from Berkshire. Berkshire's investment in Alphabet at a high-20s price-to-earnings (P/E) ratio indicates a conviction not only in Alphabet's survival but also its long-term competitive advantage in generative AI.
Image source: Getty Images.
Alphabet's advantage over start-up rivals Today, three large language models are currently regarded as the most advanced: Gemini by Alphabet, ChatGPT by OpenAI, and Claude by Anthropic. It seems as though Berkshire now believes Alphabet will win the generative AI race.
Both OpenAI and Anthropic are still private and, as of the latest data, remain unprofitable -- although Anthropic is projected to turn an operating profit for the first time this quarter. Still, Alphabet's current profitability, with $160 billion in net income over the past 12 months, dwarfs both companies' financial resources by a lot.
Aside from having much more financial resources, Alphabet also has another big cost advantage: It builds its own data centers and designs its own chips, called Tensor Processing Units. This is in contrast to OpenAI and Anthropic, which have to rent capacity from other clouds at a margin, on top of those clouds generally running more expensive Nvidia graphics processing units (GPUs).
If Alphabet has competitive AI algorithms, its current cost advantages should allow it to serve tokens to customers at a lower cost while also enabling it to provide more capacity amid insatiable demand. This could be what Berkshire sees.
An $80 billion raise could extend the advantage Both Anthropic and OpenAI have been raising capital in private markets this year, and each has filed to go public, likely later in the year. AI token demand is booming, and each needs to buy computing resources to meet it.
But Alphabet pre-empting those IPOs by raising an additional $80 billion on top of its internal cash flow not only matches the upcoming raises for Anthropic and OpenAI but could also even extend its advantage by raising this amount first.
This is because memory and chips are currently in short supply, with large companies prepaying and committing to buy semiconductors and high-bandwidth memory over multiple years. If Alphabet can make larger commitments earlier, that could box out competitors or raise the price of compute for everyone else, including Anthropic and OpenAI, who have fewer financial resources.
At this critical juncture in the AI race, with the winners yet to be determined, this strategic move could make a big difference.
There were once many search engines, too Back in the early days of the internet, before Google emerged, there were many search engines. However, Google emerged as the dominant, near-monopoly on this incredibly profitable business. It appears that Greg Abel thinks Alphabet still has the core competency to pull off a repeat with generative AI -- a market that could be multiples larger than Search is today.
SummaryCalifornia Resources stands to benefit from regulatory compromise enabling thousands of new wells in Kern County while tightening offshore restrictions.CRC’s merger with Berry Corporation enhances operational efficiency.Emerging discussion around using carbon capture to unlock unconventional oil in-state signals potential for future production expansion.I view CRC as a buy, given its robust finances, regulatory navigation, and growth opportunities from evolving California energy policy.This company is at the forefront of carbon capture.This idea was discussed in more depth with members of my private investing community, Oil & Gas Value Research. Learn More »Sitewide Sale 2026: Get 20% Off IURII KRASILNIKOV/iStock via Getty Images
California Resources (CRC) is expected to benefit from an unexpected compromise that will allow for thousands of wells in oil-rich Kern County while tightening the regulations on the offshore business. California has long
25.77K Followers
Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
Disclaimer: I am not an investment advisor, and this article is not meant to be a recommendation for the purchase or sale of stock. Investors are advised to review all company documents and press releases to see if the company fits its own investment qualifications.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.
Achieved 100% ORR and 83.3% CR rate at dose level 2 following a single infusion in patients with relapsed/refractory B-NHL in an ongoing Phase 1 study
Single infusion of LB2501 generated dose-dependent in vivo CAR-T expansion without lymphodepletion
No dose-limiting toxicities, serious adverse events, ICANS, or deaths were reported; infusion-related reactions and CRS were Grade 1–2, and none required glucocorticoids for CRS management
Additional translational data showed rapid vector clearance, polyclonal vector integration, and no evidence of non-specific transduction
Proof-of-concept progress demonstrates leadership in next-generation cell therapies, with results presented in a late-breaking session at EHA 2026
BRIDGEWATER, N.J., June 14, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced first clinical proof-of-concept data for LB2501, its investigational in vivo CD19/CD20 dual-targeting CAR-T cell therapy, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (R/R B-NHL). The results are being presented today in a late-breaking session at the European Hematology Association (EHA) 2026 Congress (Abstract #LB5006).
In the ongoing Phase 1 study, a single infusion of LB2501 generated dose-dependent in vivo CAR-T expansion without lymphodepletion. At the higher dose level (DL2), LB2501 achieved a 100% objective response rate (ORR) (6/6) and an 83.3% complete response rate (CR) (5/6), with all responses ongoing at the time of data cutoff. LB2501 also showed a favorable safety profile, with no dose-limiting toxicities (DLTs), serious adverse events (SAEs), immune effector cell-associated neurotoxicity syndrome (ICANS), or deaths reported.
“In vivo CAR-T represents a compelling frontier in cell therapy, enabling the generation of CAR-T cells directly within the patient, with the potential to simplify treatment and expand access over time,” said Ying Huang, Ph.D., Chief Executive Officer of Legend Biotech. “LB2501 is our step toward realizing that vision and reflects further progress toward our goal of leading the future of cell therapy. Backed by the commercial and scientific foundation we have built with CARVYKTI, we are well-positioned to advance this next generation of CAR-T delivery. These early data, with deep responses from a single infusion across patients, give us confidence in the path ahead.”
LB2501 Demonstrates In Vivo CAR-T Generation and Early Clinical Activity
In an ongoing Phase 1 study, 12 patients with R/R B-NHL received LB2501 across two dose levels, DL1 (n=6) and DL2 (n=6). Patients had received a median of three prior lines of therapy, and 58.3% were refractory to their most recent treatment. The open-label, multi-center, dose-escalation study is evaluating safety, recommended Phase 2 dose, pharmacokinetics, and preliminary efficacy in adults with R/R B-NHL. The study was conducted without lymphodepletion.
At DL2, LB2501 achieved a 100% ORR (6/6) and an 83.3% CR rate (5/6), with responses observed across patients with diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), and follicular lymphoma (FL). Across both dose levels, the ORR was 50.0% (6/12), and the CR rate was 41.7% (5/12). At the time of data cutoff, all responses at DL2 were ongoing.
LB2501 showed a favorable safety profile. No DLTs, SAEs, ICANS, or deaths were reported. Infusion-related reactions (IRR) and cytokine release syndrome (CRS) were the most common adverse events of special interest and were all Grade 1–2. Infusion-related reactions occurred in 75.0% (9/12) of patients overall, with a median onset of 1.4 hours after infusion and a median recovery time of 18.6 hours. CRS occurred in 66.7% (8/12) of patients overall, with a median onset at Day 11 and a median duration of 4.5 days. IRR and CRS were all Grade 1–2, no patients required glucocorticoids for CRS management. Four patients received tocilizumab.
Pharmacokinetic analyses showed dose-dependent in vivo CAR-T expansion in 100% (6/6) of patients at DL2 and 83% (5/6) of patients at DL1. CAR-T cells remained detectable in peripheral blood for up to 116 days. Viral copy number in peripheral blood peaked immediately after infusion and decreased to undetectable concentrations within 24 hours.
Additional translational analyses further characterized the in vivo profile of LB2501. No evidence of non-specific transduction was detected in NK cells or other non-T/B/NK lymphocyte populations. Vector integrations were highly polyclonal and diverse. These findings support proof-of-concept for in vivo T-cell engineering, with polyclonal vector integration and rapid vector clearance.
“These early clinical findings are encouraging in a heavily pretreated relapsed or refractory B-cell non-Hodgkin lymphoma population,” said Lei Fan, M.D., Ph.D., Professor, Doctoral Supervisor, and Administrative Director, Hematology Department, Jiangsu Province Hospital, Nanjing, China. “The responses observed at the higher dose level achieved a 100% objective response rate, together with a favorable safety profile and the absence of lymphodepletion, support further investigation of LB2501 as a novel in vivo CAR-T approach. The additional pharmacokinetic and translational findings presented at EHA further support the feasibility of generating CAR-T cells directly within the patient.” ‡
ABOUT LB2501
LB2501 is an investigational, potential first-in-class CD19/CD20 dual-targeting in vivo CAR-T therapy designed to generate CAR-T cells directly within the patient following a single intravenous infusion. It is being evaluated in an ongoing Phase 1, open-label study (NCT07002112) in patients with relapsed/refractory B-cell malignanciesi to assess safety, tolerability, and preliminary efficacy.[i]
ABOUT B-CELL NON-HODGKIN LYMPHOMA
Non-Hodgkin lymphoma (NHL) is a group of cancers that originate in lymphocytes, a type of white blood cell that plays a key role in the body’s immune system.ii B-cell lymphomas account for approximately 85% of NHL cases and arise from abnormal growth of B lymphocytes (B cells), which are responsible for producing antibodies. These malignancies include a range of subtypes that vary in aggressiveness, from slow-growing to highly aggressive disease.iii
While treatment advances have improved outcomes for some patients, those with relapsed or refractory B-cell NHL, particularly after multiple lines of therapy, often face limited options.
ABOUT LEGEND BIOTECH
With over 3,000 employees, Legend Biotech is the largest standalone cell therapy company and a pioneer in treatments that change cancer care forever. Legend Biotech is at the forefront of the CAR-T cell therapy revolution with CARVYKTI®, a one-time treatment for relapsed or refractory multiple myeloma, which it develops and markets with collaborator Johnson & Johnson. Centered in the United States, Legend Biotech is building an end-to-end cell therapy company by expanding its leadership to maximize CARVYKTI’s patient access and therapeutic potential. From this platform, Legend Biotech plans to drive future innovation across its pipeline of cutting-edge cell therapy modalities.
Learn more at https://legendbiotech.com and follow us on X, Instagram, and LinkedIn.
Statements in this press release about future expectations, plans, and prospects, as well as any other statements regarding matters that are not historical facts, constitute “forward-looking statements” within the meaning of The Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements relating to Legend Biotech’s strategies and objectives, the Phase 1 clinical trial of LB2501, and the potential benefits of LB2501, including the reproducibility and durability of any favorable results initially seen in patients dosed to date in clinical trials, and LB2501’s potential to be first-in-class. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors. Legend Biotech’s expectations could be affected by, among other things, uncertainties involved in the development of new pharmaceutical products; unexpected clinical trial results, including as a result of additional analysis of existing clinical data or unexpected new clinical data; unexpected regulatory actions or delays, including requests for additional safety and/or efficacy data or analysis of data, or government regulation generally; unexpected delays as a result of actions undertaken, or failures to act, by Legend Biotech’s third-party partners; uncertainties arising from challenges to Legend Biotech’s patent or other proprietary intellectual property protection, including the uncertainties involved in the U.S. litigation process; government, industry, and general product pricing and other political pressures; as well as the other factors discussed in the “Risk Factors” section of Legend Biotech’s Annual Report on Form 20-F filed with the Securities and Exchange Commission on March 10, 2026. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described in this press release as anticipated, believed, estimated, or expected. Any forward-looking statements contained in this press release speak only as of the date of this press release. Legend Biotech specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events, or otherwise.
‡ Lei Fan, M.D., Ph.D., Professor, Doctoral Supervisor, and Administrative Director, Hematology Department, Jiangsu Province Hospital, Nanjing, China, has provided consulting and advisory services to Legend Biotech; he has not been paid for any media work.
i ClinicalTrials.Gov. The CD19/ CD20 Dual-Target in Vivo CAR-T Lentiviral Product in the Treatment of Relapsed/ Refractory B-cell Malignancies. https://clinicaltrials.gov/study/NCT07002112. Accessed May 2026
ii American Cancer Society. “What Is Non-Hodgkin Lymphoma?”. Available at: https://www.cancer.org/cancer/types/non-hodgkin-lymphoma/about/what-is-non-hodgkin-lymphoma.html.Accessed May 2026.
iii American Cancer Society. “Types of B-cell Lymphoma.” Available at: https://www.cancer.org/cancer/types/non-hodgkin-lymphoma/about/b-cell-lymphoma.html.Accessed May 2026.
After surging to new all-time highs over a year ago, SoundHound AI (SOUN 1.21%) stock has plunged 72%. Yet the business continues to expand rapidly, with revenue surging 52% year over year in the first quarter.
Is this an ideal time to buy shares, or does the volatility signal a problem with the growth story?
Image source: Getty Images.
SoundHound AI is a volatile stock but patient investors could be rewarded. It has spent 20 years collecting data from user interactions to develop its voice AI technology. Restaurants and automakers are using it to power drive-thru ordering and in-car assistants.
The company recently unlocked another huge opportunity with its OASYS agentic AI system. This platform allows businesses to build a fleet of agents that continuously train and improve. One Fortune 100 company has already saved $10 million in quarterly costs by using SoundHound's platform.
Voice AI assistants could be one of the fastest-growing consumer applications over the next decade. The market is expected to reach $47 billion by 2034, growing nearly 35% annually, according to Market.us.
The stock's volatility largely reflects the company's lack of profitability. It reported a $26 million adjusted net loss in the first quarter 2026, and negative free cash flow of $113 million on a trailing-12-month basis. Moreover, SoundHound faces competition from tech giants like Google, which is also working on voice AI technology.
Still, SoundHound AI offers investors pure exposure to this burgeoning market. The recent pullback may provide a more attractive entry point to start a small position. The stock will remain volatile, but the long-term upside could be significant for a small AI company with a market cap close to $3 billion.
John Ballard has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Alphabet and SoundHound AI. The Motley Fool has a disclosure policy.
For technology investors, generative artificial intelligence (AI) has been the gift that just keeps giving. Money continues to pour into the sector as Wall Street and Silicon Valley both race to maximize their exposure to what could be a transformational long-term megatrend.
Sandisk (SNDK +5.24%) has been one of this year's biggest winners, with shares up by an eyepopping 600% since January. Let's dig deeper into the pros and cons of the company to decide if it is still a good buy, or if investors should consider taking some profits off the table.
Image source: Getty Images.
What is Sandisk, and why is it booming? While Sandisk is a bit of a household name, it only became publicly available as a stand-alone entity in early February when its parent company, Western Digital, divested ownership. The separation allows each company to focus on its specific niche within the market.
Both companies provide computer memory and storage, but Western Digital specializes in hard disk drives (HDDs), while Sandisk is a leader in solid state drives (SSDs). Unlike HDDs, which use moving parts to store data, SSDs operate with no mechanical components, making them faster, more reliable, and extremely energy-efficient. That last characteristic is crucial for AI data center clients that need to handle massive amounts of information while trying to minimize their costs of operation.
The performance of the two stocks has diverged sharply over the last 12 months. This highlights how SSDs are much better suited to serving the rapidly growing AI infrastructure market.
SNDK data by YCharts.
Business is booming, but what comes next? Sandisk's incredible stock price growth isn't based on hype alone. The company's fiscal third-quarter revenue soared by an eyewatering 251% year over year to $5.95 million, while gross margins rose 55.9 points to 78.4% -- a number higher than many software companies that don't even sell physical products. The combination of soaring growth and margins has caused operating income to explode by 319% to $4.11 billion.
Investors can expect Sandisk's momentum to continue in the near term because generative AI models continue to get larger and more demanding. Furthermore, hyperscalers remain committed to their data center buildouts, with analysts at Goldman Sachs projecting that total capital spending could reach $1.1 trillion in 2027.
Today's Change
(
5.24
%) $
98.59
Current Price
$
1980.10
Furthermore, some industry leaders believe memory shortages could last until 2030. If this is true, producers like Sandisk could continue enjoying the elevated margins by keeping prices high.
That said, the medium- to longer-term situation remains much more difficult to predict. It seems hard to believe that big tech companies will continue to spend sums that often exceed their cash flow on what remains a somewhat speculative technology. It could only be a matter of time before shareholders start pressuring management teams to show more restraint. That could eventually deflate the AI bubble.
Sandisk is also exposed to the cyclicality of the memory industry, which tends to experience booms and busts much like a commodity. Previous surges in memory demand (such as the PC boom in the 1990s or the smartphone boom in the 2010s) ended in sharp crashes as supply caught up to demand and prices cratered. Investors shouldn't expect the current AI-driven boom to change this long-established pattern.
While Sandisk will continue to enjoy elevated revenue and profit growth amid the AI data center boom, this won't last forever, and the risks of a correction are starting to rise. Investors who already own the stock should probably consider taking some profits off the table. Investors who missed the big rally should probably look elsewhere for value.
Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of POET Technologies Inc. (NASDAQ: POET) between April 1, 2026 and 08:57 AM ET on April 27, 2026, inclusive (the "Class Period"), of the important June 29, 2026 lead plaintiff deadline in the securities class action first filed by the Firm.
So What: If you purchased POET Technologies securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
What to do next: To join the POET Technologies class action, go to https://rosenlegal.com/submit-form/?case_id=62524 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than June 29, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.
Details of the case: According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) POET Technologies misrepresented its tax status due to it likely being deemed a passive foreign investment company (or "PFIC") under U.S. tax laws which, if not properly reported by each U.S. stockholder, would have negative tax implications for those U.S. stockholders; (2) the foregoing tax issue would, if discovered, make POET Technologies a less attractive investment than it would otherwise be, thus threatening POET Technologies' valuation; (3) Defendant Thomas Mika, despite affirming that he was not violating a non-disclosure agreement, in fact violated a business agreement by speaking about POET Technologies' business agreements in a public interview, thus endangering POET Technologies' business prospects, and (4) as a result, defendants' statements about POET Technologies' business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.
To join the POET Technologies class action, go to https://rosenlegal.com/submit-form/?case_id=62524 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.
No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm.
Attorney Advertising. Prior results do not guarantee a similar outcome.
Contact Information:
Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827 [email protected]
www.rosenlegal.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/poet-deadline-poet-investors-have-opportunity-to-lead-poet-technologies-inc-securities-fraud-lawsuit-filed-by-the-rosen-law-firm-302799396.html
By You're currently following this author! Want to unfollow? Unsubscribe via the link in your email.
Trial lawyer Mark Lanier represented the plaintiffs in the landmark social media addiction trial, where Meta CEO Mark Zuckerberg testified. Wally Skalij/Getty Images One morning in February, Mark Lanier woke up after four hours of sleep and started preparing to cross-examine one of the wealthiest people in the world: Mark Zuckerberg.
His team had worked through the night, preparing material for the day ahead that he could then review in the hours before court, all with the help of AI.
Lanier, a nationally known Texas trial lawyer with a reputation for taking on major corporations in high-stakes trials, was representing the plaintiff in a landmark social media addiction case. He said AI allowed his team to do significantly more with the limited hours they had to prep outside the courtroom during the trial, which lasted over a month.
"It's as if I have 10 additional workers who are incredibly well-trained, who know the file inside and out, who work 24 hours a day and don't even need to take a break for the restroom, much less PTO," he told Business Insider, adding, "In the 10 hours I might be working outside of court, I can get 30 hours of work done."
AI in law has been touted both as a major opportunity and a cautionary tale, with many stories of hallucinations and fake citations. While the legal industry grapples with how to use AI, Lanier said it's been a "total game changer" for him.
Lanier won the case against Meta and Google, in which the jury found the companies negligent and ruled they knew their platforms were "dangerous" but failed to warn the plaintiff, who was awarded $6 million. The case was a bellwether for thousands of similar lawsuits brought against social media companies.
Mark Lanier said using AI has transformed his workflow before and during trial. Courtesy of Mark Lanier While Lanier had used the most popular AI products, he said the AI tool he relied on before and during the trial was Boodlebox, calling it "Disney World compared to a swing set in the backyard."
A leader in the education technology space, Boodlebox provides access to major models like ChatGPT, Claude, and Gemini, allowing users to switch between them or compare results. It's also collaborative, allowing Lanier and his team of lawyers to work with the AIs in the same digital workspace.
Lanier worked with Boodlebox to create a custom license that costs him six figures annually and is tailored to his needs.
"We could, in essence, take my brain, take 42 years of my experience, take the things that I have learned and studied and published and not published and incorporate it into the brain that drove my AI queries and results," he said.
He relied on AI before and during the landmark trialLanier is careful when talking specifics about how he deploys his AI. He says it's a matter of "trade craft" and that his firm is "doing some things that nobody else is doing."
One example he gave included taking transcripts from court each day and asking different models to evaluate them. He said AI is also great for finding a more creative or visceral way to describe something in court. He even would feed AI jury notes that came up during deliberations and ask it to evaluate where the jury was in the process.
At the end of court each day, they'd meet in his war room, debrief, and assign tasks to everyone, such as pulling the five most critical documents supporting point A. The team would then break and do much of that work in Boodlebox, allowing him to review what they've put together and how. He said he and his team, which includes several of his daughters, spent thousands of hours on the platform.
While most of Boodlebox's clients are big universities, a company representative told Business Insider that the platform is also exploring more enterprise and law adoption, in part because of its work with Lanier.
Lanier said he doesn't use AI in the way that often gets people into trouble. "I'm not going to say, 'Go do my research and write my brief,'" he said, adding that there was one instance in the case where AI cited something from the record and he knew it wasn't correct.
"It's not unbridled," he said. "You are an important part of the equation."
His advice to other lawyers trying to use AI was to keep up with the developments in the rapidly evolving field. He has an AI team at his firm that sends him a document every Friday with all the developments in AI, typically three pages single-spaced.
"Next trial, I will make what I did last trial look like Fred Flintstone and the Stone Age," he said.
Read next
Kelsey Vlamis You're currently following this author! Want to unfollow? Unsubscribe via the link in your email.
Kelsey is a senior reporter for Business Insider, where she covers business and tech news as well as stories about travel, luxury, and consulting.Her feature story "Disaster at 18,200 feet" received awards from the New York Press Club and the North American Travel Journalists Association, as well as honorable mention from the Society of American Travel Writers. It was also included on Longreads' and Pocket's best of 2022 lists. She has also received an American Journalism Online Award for her coverage on missing and murdered Indigenous people in Wyoming.She's appeared on CBS, NPR, NBC, and other outlets to discuss her work. She previously worked on the world news desk at the BBC in London and received a master's in journalism from Northwestern University.She can be reached by email at [email protected] or via the encrypted-messaging app Signal @kelseyv.21.Popular storiesDisaster on Denali: Inside a 1,000-foot fall on America's highest peakThrifting is more popular than ever. It's also never been worse.Rolex wouldn't service the vintage watch my mom inherited. Watchmakers say it happens all the time.A tiny, invasive bug and the climate crisis are changing how guitars are made, and shifting the course of music historyThe tourism free-for-all is overGovernment-run boarding schools were founded to 'civilize' Native Americans. Hundreds of dead children remain buried in the schoolyard graves.Meet the Texas minister who helps fly dozens of women to New Mexico every month to get abortionsPeople are flocking to Colorado for the great outdoors, but the air pollution is so bad, it's forcing many to stay insideInside Kabul: An aid worker reveals the devastating chaos that erupted during the US exit from Afghanistan
Tech giant and Google parent company Alphabet (GOOGL +0.53%)(GOOG +0.45%) has spent billions of dollars buying back its stock over the past decade. But Alphabet is reversing course in a big way, announcing a massive $84.75 billion equity offering earlier this month.
In other words, Alphabet is selling new shares of stock to raise capital to fund its artificial intelligence (AI) investments. Alphabet has primarily funded its AI spending over the past several years with cash flow. Now, the company is pulling out the stops to win the AI war it's waging with other hyperscalers, including OpenAI and Anthropic. Alphabet plans to spend $180 billion to $190 billion this year alone.
However, it's not clear right now whether that's something investors should celebrate or fear. The AI equity raise could have two implications for Alphabet stock.
Image source: The Motley Fool
1. Alphabet is seeing AI's early returns and leaning in The AI boom really began to pick up steam in 2023, and you can see how Alphabet's capital expenditures have continued to grow since then. The company developed its Gemini AI models, launched an app to compete with ChatGPT, and integrated Gemini AI across Google Search and other products and services.
At this point, Alphabet seems to be seeing positive returns from AI across its business. AI has boosted its cloud computing business, helped Waymo grow, and is enabling Google Search to remain relevant in the AI era.
GOOGL Capital Expenditures (TTM) data by YCharts
Additionally, Alphabet reached an agreement with Apple earlier this year to power its next-generation frontier AI models with Gemini. There are roughly 2.5 billion active iOS devices worldwide, so this is a massive lift that naturally will require more AI infrastructure to support it. So, the positive angle here is that Alphabet can justify this AI spending with years of growth ahead.
Today's Change
(
0.53
%) $
1.90
Current Price
$
359.67
2. Investors are now paying Alphabet's AI bill The unfortunate aspect of this is the shift in funding strategy. It's one thing to use cash profits to build out AI, but the equity raise means that existing shareholders will see their stock diluted. To be fair, the near-term dilution is relatively minor. The $84.75 billion equity raise only represents about 2% of Alphabet's current $4.3 trillion market cap.
Alphabet's balance sheet leverage is only 0.33 times its EBITDA (earnings before interest, taxes, depreciation, and amortization), so the company could easily afford to take on that debt. But it could be that management felt a 2% dilution was cheaper than paying interest on that debt.
Investors probably don't want to see Alphabet make this a long-term habit, as those raises could add up to significant dilution over the years. Remember, issuing new shares also means the company is paying dividends on those shares. That said, this equity raise should raise no red flags right now, since the upside AI offers is too great an opportunity to pass up.
The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Microsoft Corporation (“Microsoft” or “the Company”) (NASDAQ: MSFT) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Investors who purchased the Company’s securities between May 1, 2025 and January 28, 2026, inclusive (the “Class Period”), are encouraged to contact the firm before August 11, 2026.
If you are a shareholder who suffered a loss, click here to participate.
We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at [email protected].
The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.
According to the Complaint, the Company made false and misleading statements to the market. Microsoft’s Copilot AI products suffered from problems ranging from poor user experience to capacity limitations. The Company’s AI model ranked poorly against competitors on industry benchmark tests. The Company would need to spend billions on capital expenditures related to AI including diverting hardware away from profitable business units to improve its competitive posture in artificial intelligence. The Company was incapable of converting a large percentage of Microsoft 365 users to paid Copilot subscriptions, losing market share to rivals. Based on these facts, the Company’s public statements were false and materially misleading throughout the class period. When the market learned the truth about Microsoft, investors suffered damages.
Join the case to recover your losses
The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260613313708/en/
Space Exploration Technologies (SPCX +19.22%), known as SpaceX, is attracting a lot of attention, as it should. It's the largest IPO the world has ever seen, led by the visionary Elon Musk. Although Musk may be a polarizing figure, there's no denying the success he's delivered to investors so far through Tesla.
While investors may want Tesla-like returns, achieving them with SpaceX will be nearly impossible given its sheer size. Instead, I think investors should focus on other stocks that look like great values or are growing at lightspeed. These all appear to be better investments than SpaceX and will make investors far more money over the next few years.
Image source: Getty Images.
1. Microsoft Microsoft (MSFT +0.11%) may sound like a boring old investment, which may be partially true. However, it has a few things going for it.
First, it's well off its all-time highs. The market has turned sour on Microsoft's stock despite the company's excellence in many areas, specifically in artificial intelligence (AI). Its AI product lineup grew annual recurring revenue by 123% to $37 billion during its most recent quarter.
Today's Change
(
0.11
%) $
0.42
Current Price
$
390.76
Additionally, its cloud computing division, Azure, increased revenue by 40%. Overall, Microsoft's quarterly revenue rose at an 18% pace to $82.9 billion. For reference, SpaceX's 2025 revenue totaled $18.7 billion, up 33%.
Microsoft is also attractively valued, trading at one of the lowest price-to-earnings (P/E) ratios the market has seen in a while.
MSFT PE Ratio data by YCharts
While SpaceX may be the flashy stock, Microsoft is the workhorse that will deliver for investors over the long term. As a result, I think it's an excellent buy right now.
2. Nebius Group If Microsoft is growing too slowly for your liking, Nebius (NBIS +4.63%) might be a better pick. In one aspect, Nebius and SpaceX may be head-to-head competitors.
Nebius is a neocloud company specializing in AI-ready cloud computing. Part of SpaceX's business plan is to launch AI data centers into space, and whether it's a success remains to be seen.
Today's Change
(
4.63
%) $
10.28
Current Price
$
232.52
One thing that isn't up for debate is Nebius's success right now. In the first quarter, it grew revenue by 684% year over year. That's not the end of it, either. Wall Street analysts expect 550% revenue growth for 2026 and 225% in 2027. SpaceX can only dream of growth like that, and it doesn't have any divisions remotely close to Nebius's growth rate.
I think Nebius is primed to continue growing rapidly and will easily outpace SpaceX over the next few years, making it a better stock pick.
3. Nvidia If you're looking for a combination of growth and value, then Nvidia (NVDA +0.15%) is your ticket.
The world's largest company makes GPUs that power AI workloads in data centers. It's growing at a remarkable pace right now and is expected to keep that up for some time. For fiscal year (FY) 2027 (ending January 2027), Wall Street analysts expect 81% growth and 41% in FY 2028. Those are both faster growth rates than SpaceX is currently growing, and Nvidia can also be purchased at a pretty attractive valuation.
NVDA PE Ratio data by YCharts
At 31 times earnings, it's not particularly expensive, especially compared to other tech stocks like Apple and Amazon, which trade at 36 and 29 times earnings, respectively. Neither of these (or any other big tech stock, including SpaceX) has growth remotely close to Nvidia.
Nvidia is a rare combination of growth and value and will likely result in huge returns. I think it will easily outperform SpaceX moving forward, and I'm putting my money there instead of the latest hot IPO.
Keithen Drury has positions in Amazon, Microsoft, Nebius Group, Nvidia, and Tesla. The Motley Fool has positions in and recommends Amazon, Apple, Microsoft, Nvidia, and Tesla. The Motley Fool has a disclosure policy.
General Motors said it will roll out eyes-off driving on highways in 2028, starting with the Cadillac Escalade IQ. Tayfun Coskun/Anadolu via Getty Images General Motors may have shut down its dedicated robotaxi division, but it hasn't bowed out of the race.
Sterling Anderson, the former head of Tesla's Autopilot program and GM's chief product officer, told Business Insider in an interview that the company's focus on autonomy in personal cars could be applied to driverless ride-hailing services in the future.
Anderson said GM's approach is to develop self-driving technology by breaking the driving experience into pieces and examining where autonomy is most useful to car owners. That means first tackling long stretches of highway driving before expanding to arterial roads and urban centers.
Over time, the executive said GM's autonomous driving systems will be able to operate in enough regions to make a viable robotaxi service.
"Ultimately, the two converge. Our operating region looks identical to the operating region of a robotaxi company," he said. "The question at that point becomes, 'Why not offer them in a robotaxi-type application as well?'"
GM was once seen as one of the leading challengers to Alphabet's Waymo robotaxis, pouring more than $10 billion into Cruise, the robotaxi startup that it acquired in 2016. The division was shut down in 2024 after facing regulatory hurdles and a safety incident that forced Cruise to pause testing in California.
GM pulled the plug on its robotaxi business, Cruise, in 2024 and has since shifted its resources to personal autonomy. David Paul Morris/Bloomberg via Getty Images GM has since shifted its focus toward its hands-off, eyes-on driver assistance tech called Super Cruise, akin to Tesla Full Self-Driving. The company said in April that GM customers have driven one billion hands-free miles with the feature and that it plans to introduce eyes-off highway driving in 2028.
The shift has come with a rebuilding of GM's autonomous-driving ranks. Business Insider reported in December that it had hired Ronalee Mann, a former Cruise and Tesla executive, for its renewed self-driving focus inside the company. The Information reported last week that GM has rehired about 100 former Cruise employees to develop eyes-off driving capabilities.
Several other legacy automakers and EV startups are charting their own path to robotaxis. Hyundai-backed Motional launched a robotaxi service with Uber in Las Vegas this year and plans to commercialize fully driverless rides there by the end of 2026. Rivian is also developing autonomous driving for a future robotaxi fleet. The EV maker announced a $1.25 billion robotaxi deal with Uber in March.
While GM isn't jumping headfirst into a robotaxi play, Anderson said the company will be prepared to meet the demand.
"We'll be ready for it," he said. "If that's where the world goes, our autonomous vehicles will be capable of being robotaxis as well."
Have a tip? Contact this reporter via email at [email protected] or Signal at lloydlee.71. Use a personal email address, a nonwork WiFi network, and a nonwork device; here's our guide to sharing information securely.
Read next
Lloyd Lee You're currently following this author! Want to unfollow? Unsubscribe via the link in your email.
SummaryRevenue growth is recovering, led by AI data center momentum and stabilization in automotive and industrial segments, though automotive faces competitive risks in China.Margin expansion is driven by utilization gains, Treo product scaling, and normalized capex, with gross margin projected to reach 54.4% and EBIT margin 39.2% by 2030.Valuation rerating is justified by stronger forward earnings and profitability outlooks, with upside potential from Fab Right initiatives and continued AI data center growth. JHVEPhoto/iStock Editorial via Getty Images
By Anthony Goh, Senior Investment Research Analyst @ Khaveen Investments
In our previous analysis, we expected ON Semiconductor (ON) to benefit from a recovery in the automotive and industrial markets, supporting revenue growth
8.36K Followers
Analyst’s Disclosure: I/we have a beneficial long position in the shares of ON either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
Khaveen Investments is registered as an investment adviser with the U.S. Securities and Exchange Commission (SEC). Registration with the U.S. SEC does not imply a certain level of skill or training. No information in this publication is intended as investment, tax, accounting, or legal advice, or as an offer/solicitation to sell or buy. Material provided in this publication is for educational purposes only and was prepared from sources and data believed to be reliable, but we do not guarantee its accuracy or completeness.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.
Genmab A/S (Nasdaq: GMAB) today announced new data from two studies evaluating epcoritamab, a T-cell engaging antibody administered subcutaneously, in the first-line (1L) treatment of patients with diffuse large B-cell lymphoma (DLBCL) who may have limited treatment options due to advanced age or multiple health conditions. Results from the Phase 2 EPCORE® DLBCL-3 study showed an overall response rate (ORR) of 67% and a complete response (CR) rate of 58% with epcoritamab monotherapy in elderly patients with newly diagnosed DLBCL. In the Phase 1b/2 EPCORE NHL-2 study, epcoritamab plus rituximab plus dose-attenuated cyclophosphamide, doxorubicin, vincristine, and prednisone (R-mini-CHOP) demonstrated an ORR of 93% and a CR rate of 86% in elderly patients with newly diagnosed DLBCL.
The results from both studies were presented in two poster presentations (abstracts PS2082 and PF1007) at the European Hematology Association (EHA) 2026 Congress held in Stockholm, Sweden, June 11-14. Additionally, the full EPCORE DLBCL-3 results have been simultaneously published in The Lancet Haematology.
EPCORE DLBCL-3 Results
The Phase 2 EPCORE DLBCL-3 study (abstract PS2082) evaluated the efficacy and safety of fixed-duration epcoritamab monotherapy in newly diagnosed CD20+ large B-cell lymphoma (LBCL) patients ineligible for anthracycline-based chemotherapy due to age (≥80 years) or comorbidities (≥75 years with comorbidities). Among 66 enrolled patients, the median age was 82.5 years, and all had comorbid conditions (94% with ≥3 comorbidities). With a median follow-up of 21.9 months, epcoritamab monotherapy demonstrated responses in this population with high unmet medical need.
An ORR of 67% and a CR rate of 58% were observed in evaluable patients (n=66). Median time to response was 1.5 months, and median time to CR was 2.2 months. Notably, 11 of 17 patients with a partial response or stable disease at first assessment subsequently achieved a CR.
"For newly diagnosed elderly patients with diffuse large B-cell lymphoma and comorbidities, who are often excluded from standard curative chemotherapy and ineligible for doxorubicin, finding more options is paramount," said Umberto Vitolo, M.D. Candiolo Cancer Institute, FPO-IRCCS, Candiolo (Turin), Italy. "The EPCORE DLBCL-3 study showed that epcoritamab monotherapy offers robust data. Importantly, its safety profile, including cytokine release syndrome and immune effector cell–associated neurotoxicity syndrome, was consistent with expected rates in this fragile population with a high unmet medical need for new therapeutic options."
Responses were durable, with median duration of response (DOR) and duration of complete response (DOCR) not reached. At 12 months, an estimated 67% of responses and 73% of CRs remained ongoing. Median progression-free survival (PFS) was 13.0 months, while median overall survival (OS) was not reached; an estimated 43% of patients remained progression-free and 62% were alive at 18 months. High rates of minimal residual disease (MRD) negativity were observed, with 92% of evaluable responders achieving MRD negativity, typically by Cycle 3 Day 1 and sustained through Cycle 12 Day 1 in most patients.
The safety profile was consistent with expected rates in this elderly population. Cytokine release syndrome (CRS) occurred in 71% of patients, most commonly during Cycle 1, and immune effector cell-associated neurotoxicity syndrome (ICANS) occurred in 18%. Infections of any grade occurred in 68% of patients (26% Grade ≥3), and neutropenia was reported in 16%, with no febrile neutropenia or clinical tumor lysis syndrome observed. Eight Grade 5 TEAEs occurred.
EPCORE NHL-2, Arm 8 Results
Arm 8 of the Phase 1b/2 EPCORE NHL-2 study (abstract PF1007) evaluated epcoritamab plus R-mini-CHOP in 28 newly diagnosed CD20+ DLBCL patients ineligible for full-dose R-CHOP due to age (≥75 years) or comorbidities (≥65 years with comorbidities). With more than two years of follow-up, fixed-duration epcoritamab plus R-mini-CHOP demonstrated high response rates, sustained MRD negativity and durable remissions.
An ORR of 93% and a CR rate of 86% were observed. Median DOR, DOCR, PFS, and OS were not reached. At two years, estimated DOR and DOCR rates were 79%, while estimated PFS and OS rates were 76% and 82%, respectively.
“The EPCORE NHL-2 Arm 8 results are very encouraging, showing that combining epcoritamab with R-mini-CHOP led to high overall response rates and complete response rates, rapid and sustained minimal residual disease negativity, and durable remissions in this population,” said David Belada, M.D., Department of Internal Medicine—Haematology, Charles University, Hospital and Faculty of Medicine, Hradec Králové, Czech Republic. “These outcomes, alongside a consistent safety profile, potentially support the integration of epcoritamab with standard of care for these vulnerable patients, and highlight its broad utility in combinations across a range of disease settings and patient populations."
Rapid and sustained MRD negativity was observed, with 95% of evaluable patients achieving MRD negativity, including high rates in high-risk subgroups. Outcomes compared favorably with historical results for R-mini-CHOP alone.
The safety profile was consistent with prior reports and the known safety profiles of epcoritamab and R-mini-CHOP. The most common Grade ≥3 treatment-emergent adverse events (TEAEs) were neutropenia (54%), serious infections (33%) and anemia (14%). Most Grade ≥3 serious infections occurred during the first six cycles of treatment with R-mini-CHOP coadministration. TEAEs led to epcoritamab discontinuation in three patients (11%).
“Genmab is committed to evaluating epcoritamab as a potential treatment option in earlier lines of therapy for patients who traditionally struggle with aggressive treatment," said Dr. Judith Klimovsky, Executive Vice President and Chief Development Officer of Genmab. "The robust data observed in both the monotherapy and combination approaches reinforce our vision of making epcoritamab a foundational therapy across the spectrum of B-cell malignancies. These Phase 2 results support our ongoing commitment to addressing the significant unmet medical needs of elderly and comorbid patients, as we seek to identify effective, less intensive and tolerable options."
About Diffuse Large B-Cell Lymphoma
Diffuse large B-cell lymphoma (DLBCL) DLBCL is the most common type of non-Hodgkin lymphoma (NHL) worldwide, accounting for approximately 25-30 percent of all NHL cases.i,ii DLBCL can arise in lymph nodes as well as in organs outside of the lymphatic system, occurs more commonly in the elderly and is slightly more prevalent in men.iii,iv DLBCL is a fast-growing type of NHL, a cancer that develops in the lymphatic system and affects B-cell lymphocytes, a type of white blood cell. For many people living with DLBCL, their cancer either relapses, which means it may return after treatment, or becomes refractory, meaning it does not respond to treatment. Although new therapies have become available, treatment management can remain a challenge.iv,v
About the EPCORE® DLBCL-3 Trial
EPCORE DLBCL-3 (NCT05660967) is an open-label, randomized, global, Phase 2 trial to evaluate the efficacy and safety of epcoritamab as monotherapy or in combination with lenalidomide as first-line therapy for anthracycline-ineligible subjects with diffuse large B-cell lymphoma (DLBCL). This is a 2-stage trial. In Stage 1, eligible patients were randomized to either epcoritamab monotherapy or epcoritamab plus lenalidomide. In Stage 2, additional patients were enrolled to the epcoritamab monotherapy arm. Each treatment cycle is 28 days. Patients will receive a maximum of 12 cycles (up to 1 year) of treatment. The primary objective is to evaluate the clinical efficacy of epcoritamab monotherapy or epcoritamab and lenalidomide. The primary endpoint is to achieve a complete response rate determined by Lugano criteria. Additional secondary endpoints include overall response rate, duration of response, duration of complete response, rate of minimal residual disease negativity, progression-free survival and overall survival.
More information on this trial can be found at www.clinicaltrials.gov/.
About the EPCORE® NHL-2 Trial
EPCORE NHL-2 (NCT04663347) is a Phase 1b/2 open-label interventional trial to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics/biomarkers, immunogenicity, and preliminary efficacy of epcoritamab as a monotherapy and in combination with other standard of care agents in patients with B-cell non-Hodgkin lymphoma (B-NHL). The trial consists of two parts: Part 1 (Dose Escalation) and Part 2 (Dose Expansion). The primary objective of Part 1 is safety, and the primary goal of Part 2 is preliminary efficacy. The primary efficacy endpoint is overall response rate (ORR) based on best overall response per Lugano criteria. MRD negativity was assessed as a secondary endpoint.
More information on this trial can be found at www.clinicaltrials.gov.
About Epcoritamab
Epcoritamab is an IgG1-bispecific antibody created using Genmab's proprietary DuoBody technology and administered subcutaneously. Genmab's DuoBody-CD3 technology is designed to direct cytotoxic T cells selectively to elicit an immune response toward target cell types. Epcoritamab is designed to simultaneously bind to CD3 on T cells and CD20 on B cells and induces T-cell-mediated killing of CD20+ cells.vi
Epcoritamab (approved under the brand name EPKINLY® in the U.S. and Japan, and TEPKINLY® in the EU) has received regulatory approval in certain lymphoma indications in more than 65 territories. Where approved, epcoritamab is a readily accessible therapy. Epcoritamab is being co-developed by Genmab and AbbVie as part of the companies' oncology collaboration. The companies share commercial responsibilities in the U.S. and Japan, with AbbVie responsible for further global commercialization. Both companies will pursue additional international regulatory approvals for the investigational relapsed or refractory (R/R) follicular lymphoma (FL) indication and additional approvals for the R/R diffuse large B-cell lymphoma (DLBCL) indication.
Genmab and AbbVie continue to evaluate the use of epcoritamab as a monotherapy, and in combination, across lines of therapy in a range of hematologic malignancies. This includes several Phase 3, open-label, randomized trials, including a trial evaluating epcoritamab in combination with R-CHOP in adult patients with newly diagnosed DLBCL (NCT05578976), a trial evaluating epcoritamab in combination with lenalidomide compared to chemotherapy infusion in patients with R/R DLBCL (NCT06508658), and a trial evaluating epcoritamab in combination with lenalidomide and rituximab (R2) compared to chemoimmunotherapy in patients with previously untreated FL (NCT06191744). The safety and efficacy of epcoritamab has not been established for these investigational uses. Please visit www.clinicaltrials.gov for more information.
What is EPKINLY?
EPKINLY is a prescription medicine used to treat adults with:
certain types of diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma that has come back (relapsed) or that did not respond (refractory) after 2 or more treatments. follicular lymphoma (FL) that has come back or that did not respond to previous treatment, together with lenalidomide and rituximab follicular lymphoma (FL) that has come back or that did not respond after 2 or more treatments. EPKINLY for the treatment of DLBCL is approved based on patient response data. Studies are ongoing to confirm the clinical benefit of EPKINLY.
It is not known if EPKINLY is safe and effective in children.
IMPORTANT SAFETY INFORMATION
Important Warnings—EPKINLY can cause serious side effects, including:
Cytokine release syndrome (CRS), which is common during treatment with EPKINLY and can be serious or lead to death. To help reduce your risk of CRS, you will receive EPKINLY on a step-up dosing schedule (when you receive 2 or 3 smaller step-up doses of EPKINLY before your first full dose during your first cycle of treatment), and you may also receive other medicines before and for 3 days after receiving EPKINLY. If your dose of EPKINLY is delayed for any reason, you may need to repeat the step-up dosing schedule. Neurologic problems that can be serious, and can be life-threatening, and lead to death. Neurologic problems may happen days or weeks after you receive EPKINLY. People with DLBCL or high-grade B-cell lymphoma may be hospitalized after receiving their first full dose of EPKINLY on Day 15 of Cycle 1 due to the risk of CRS and neurologic problems.
People with FL may be hospitalized after receiving their first full dose of EPKINLY on Day 22 of Cycle 1 due to the risk of CRS and neurologic problems.
Tell your healthcare provider or get medical help right away if you develop a fever of 100.4°F (38°C) or higher; dizziness or lightheadedness; trouble breathing; chills; fast heartbeat; feeling anxious; headache; confusion; shaking (tremors); problems with balance and movement, such as trouble walking; trouble speaking or writing; confusion and disorientation; drowsiness, tiredness or lack of energy; muscle weakness; seizures; or memory loss. These may be symptoms of CRS or neurologic problems. If you have any symptoms that impair consciousness, do not drive or use heavy machinery or do other dangerous activities until your symptoms go away.
EPKINLY can cause other serious side effects, including:
Infections that may lead to death. Your healthcare provider will check you for signs and symptoms of infection before and during treatment and treat you as needed if you develop an infection. You should receive medicines from your healthcare provider before you start treatment to help prevent infection. Tell your healthcare provider right away if you develop any symptoms of infection during treatment, including fever of 100.4°F (38°C) or higher, cough, chest pain, tiredness, shortness of breath, painful rash, sore throat, pain during urination, feeling weak or generally unwell, or confusion. Low blood cell counts, which can be serious or severe. Your healthcare provider will check your blood cell counts during treatment. EPKINLY may cause low blood cell counts, including low white blood cells (neutropenia and lymphopenia), which can increase your risk for infection; low red blood cells (anemia), which can cause tiredness and shortness of breath; and low platelets (thrombocytopenia), which can cause bruising or bleeding problems. Your healthcare provider will monitor you for symptoms of CRS, neurologic problems, infections, and low blood cell counts during treatment with EPKINLY. Your healthcare provider may temporarily stop or completely stop treatment with EPKINLY if you develop certain side effects.
Before you receive EPKINLY, tell your healthcare provider about all your medical conditions, including if you have an infection, are pregnant or plan to become pregnant, or are breastfeeding or plan to breastfeed. If you receive EPKINLY while pregnant, it may harm your unborn baby. If you are a female who can become pregnant, your healthcare provider should do a pregnancy test before you start treatment with EPKINLY and you should use effective birth control (contraception) during treatment and for 4 months after your last dose of EPKINLY. Tell your healthcare provider if you become pregnant or think that you may be pregnant during treatment with EPKINLY. Do not breastfeed during treatment with EPKINLY and for 4 months after your last dose of EPKINLY.
The most common side effects of EPKINLY when used alone in DLBCL or high-grade B-cell lymphoma or FL include CRS, injection site reactions, tiredness, muscle and bone pain, fever, diarrhea, COVID-19, rash, and stomach-area (abdominal) pain. The most common severe abnormal laboratory test results with EPKINLY when used alone include decreased white blood cells, decreased red blood cells, and decreased platelets.
The most common side effects of EPKINLY when used together with lenalidomide and rituximab in FL include rash, upper respiratory tract infections, tiredness, injection site reactions, constipation, diarrhea, CRS, pneumonia, COVID-19, and fever. The most common severe abnormal laboratory test results with EPKINLY when used together with lenalidomide and rituximab include decreased white blood cells and decreased platelets.
These are not all of the possible side effects of EPKINLY. Call your doctor for medical advice about side effects.
You are encouraged to report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch or to Genmab US, Inc. at 1-855-4GENMAB (1-855-443-6622).
Please see Medication Guide, including Important Warnings.
About Genmab
Genmab is an international biotechnology company dedicated to improving the lives of people with cancer and other serious diseases through innovative antibody medicines. For over 25 years, its passionate, innovative and collaborative team has advanced a broad range of antibody-based therapeutic formats, including bispecific antibodies, antibody–drug conjugates (ADCs), immune-modulating antibodies and other next-generation modalities. Genmab’s science powers eight approved antibody medicines, and the company is advancing a strong late-stage clinical pipeline, including wholly owned programs, with the goal of delivering transformative medicines to patients.
Established in 1999, Genmab is headquartered in Copenhagen, Denmark, with international presence across North America, Europe and Asia Pacific. For more information, please visit Genmab.com and follow us on LinkedIn and X.
This Media Release contains forward looking statements. The words “believe,” “expect,” “anticipate,” “intend” and “plan” and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with preclinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products or technologies obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab’s most recent financial reports, which are available on www.genmab.comand the risk factors included in Genmab’s most recent Annual Report on Form 20-F and other filingswith the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov. Genmab does not undertake any obligation to update or revise forward looking statements in this Media Release nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law.
Genmab A/S and/or its subsidiaries own the following trademarks: Genmab®; the Y-shaped Genmab logo®; Genmab in combination with the Y-shaped Genmab logo®; HuMax®; DuoBody®; HexaBody®; DuoHexaBody®, HexElect® and KYSO®. EPCORE®, EPKINLY®, TEPKINLY® and their designs are trademarks of AbbVie Biotechnology Ltd.
____________________ i Lymphoma Research Foundation. Diffuse Large B-Cell Lymphoma. Accessed February 2026. https://lymphoma.org/understanding-lymphoma/aboutlymphoma/nhl/dlbcl/
ii Padala, et al. Diffuse Large B-Cell Lymphoma. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan. 2023 Apr 24.
iii Sehn, et al. Diffuse Large B-Cell Lymphoma. N Engl J Med. 2021;384:842-858. doi: 10.1056/NEJMra2027612.
iv Kanas, et al. Epidemiology of Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL) in the United States and Western Europe: Population-Level Projections for 2020-2025. Leuk Lymphoma. 2022;63(1):54-63. doi: 10.1080/10428194.2021.1975188.
v Crump, et al. Outcomes in Refractory Diffuse Large B-Cell Lymphoma: Results From the International SCHOLAR-1 Study. Blood. 2017;130(16):1800-1808. doi: 10.1182/blood-2017-03-769620.
vi Engelberts PJ, Hiemstra IH, de Jong B, et al. DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosing. EBioMedicine. 2020;52:102625. DOI: 10.1016/j.ebiom.2019.102625.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260610278575/en/
Did you buy VRRM common stock between February 24, 2026 and May 26, 2026?
Affected VRRM Investor Summary
Who: Verra Mobilty Corporation (NASDAQ: VRRM)What: Securities fraud class action lawsuit filedClass Period: February 24, 2026 through May 26, 2026Deadline to Seek Lead Plaintiff Status: August 4, 2026Key Lawsuit Allegations: Material misstatements and/or omissions concerning the company's continued growth in its Commercial Services business and contract with Avis Budget Group.Investor Action: Contact Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) for recovery options, /PRNewswire/ -- Kessler Topaz Meltzer & Check, LLP (www.ktmc.com), a nationally recognized securities litigation law firm, informs investors that a securities fraud class action lawsuit has been filed against Verra Mobility Corporation (Verra) (NASDAQ: VRRM) on behalf of those who purchased or acquired Verra common stock between February 24, 2026 and May 26, 2026, inclusive. The lawsuit is filed in the United States District Court for the District of Arizona and is captioned Otucu v. Verra Mobility Corporation, Case No.2:26-cv-03973 (D. Ariz.). Investors have until August 4, 2026, to file for lead plaintiff status.
CONTACT KTMC TO DISCUSS YOUR LEGAL RIGHTS:
If you purchased or acquired Verra common stock and have lost money on your investment, you are encouraged to contact KTMC attorney Jonathan Naji, Esq. at:
There is no cost or obligation to speak with an attorney.
VERRA MOBILITY CORPORATION CLASS ACTION LAWSUIT - COMPLAINT ALLEGATION SUMMARY:
The complaint alleges that, throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the company's business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) Verra's optimistic plan for continued growth in its Commercial Services business was dependent on its relationship with Avis, and in particular obtaining a contract extension with Avis Budget Group; (2) Verra minimized concerns that major rent-a-car customers could replace Verra with in-house solutions or outsourced alternatives, making Verra's 2026 full year guidance increasingly unlikely to be met; and (3) as a result, Defendants' positive statements about the company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.
Why did Verra's Stock Drop?
On May 26, 2026, Verra disclosed that the company had received a termination notice from Avis Budget Group regarding its contract, which becomes effective in September 2026. Verra further disclosed that it "expects the termination to reduce Commercial Services' 2026 annualized revenue by approximately $135 million to $145 million and 2026 annualized segment profit by approximately $120 million to $125 million, before taking into account expected cost reduction initiatives." Verra accordingly lowered its full year 2026 financial outlook. On this news, Verra's stock price fell $9.23 per share, or 70.6%, to close at $3.85 per share on May 27, 2026.
On June 1, 2026, Verra announced that its President and Chief Executive Officer had been terminated as "the Board determined that a change in leadership [was] needed[.]"
WHAT VRRM INVESTORS CAN DO NOW:
File to be lead plaintiff by August 4, 2026.Contact KTMC for a free case evaluation. All representation is on a contingency fee basis, there is no cost to you.Retain counsel of choice or take no action.THE LEAD PLAINTIFF PROCESS FOR VERRA MOBILITY CORPORATION INVESTORS:
Verra investors may, no later than August 4, 2026, seek to be appointed as a lead plaintiff representative of the class through Kessler Topaz Meltzer & Check, LLP or other counsel, or may choose to do nothing and remain an absent class member. A lead plaintiff is a representative party who acts on behalf of all class members in directing the litigation. The lead plaintiff is usually the investor or small group of investors who have the largest financial interest and who are also adequate and typical of the proposed class of investors. The lead plaintiff selects counsel to represent the lead plaintiff and the class and these attorneys, if approved by the court, are lead or class counsel. Your ability to share in any recovery is not affected by the decision of whether or not to serve as a lead plaintiff.
Kessler Topaz Meltzer & Check, LLP encourages Verra investors to contact the firm for more information.
ABOUT KESSLER TOPAZ MELTZER & CHECK, LLP (KTMC):
Kessler Topaz Meltzer & Check, LLP (KTMC) is a leading U.S. plaintiff-side law firm focused on securities-fraud class actions and global investor protection. The firm represents individual investors as well as institutions, such as major pension funds, asset managers, and international investors. KTMC has led some of the largest recoveries in securities litigation and has been recognized by peers and the legal media with numerous accolades, including The National Law Journal's Plaintiff's Hot List and Trailblazers in Plaintiffs' Law, BTI Consulting Group's Honor Roll of Most Feared Law Firms, The Legal Intelligencer's Class Action Firm of the Year, Lawdragon's Leading Plaintiff Financial Lawyers, and Law360's Titans of the Plaintiffs Bar. The firm operates globally with offices in Pennsylvania and California. KTMC has recovered over $25 billion for our clients and the classes they represent. For more information about Kessler Topaz Meltzer & Check, LLP, please visit www.ktmc.com. The complaint in this matter was not filed by KTMC.
CONTACT:
Jonathan Naji, Esq.
(484) 270-1453
280 King of Prussia Road
Radnor, PA 19087 [email protected]
May be considered attorney advertising in certain jurisdictions. Past results do not guarantee future outcomes.
View original content to download multimedia:https://www.prnewswire.com/news-releases/verra-mobility-corporation-vrrm-securities-fraud-class-action-lawsuit-filed-august-4-2026-lead-plaintiff-deadline-302799274.html
Obie Mckenzie, Director at Sharplink (SBET +1.47%), reported the direct sale of 12,892 shares for a transaction value of ~$96,000 on May 12, 2026, according to a SEC Form 4 filing.
Transaction summaryMetricValueShares sold (direct)12,892Transaction value~$96,000Post-transaction shares (direct)24,998Post-transaction value (direct ownership)~$179,000Transaction value based on SEC Form 4 weighted average purchase price ($7.41).
Key questionsHow does this transaction impact Mckenzie’s ownership in Sharplink?
The sale represents a 34.02% reduction in direct holdings, with Mckenzie retaining 24,998 shares directly and no indirect or derivative positions as of May 12, 2026.Was there any indirect or derivative activity associated with this trade?
All shares sold were held directly by Mckenzie; there were no indirect entities involved and no stock options or other derivative securities exercised or disposed.What is the historical context of this sale relative to prior transactions?
This filing marks Mckenzie's second open market sale in nine months, following a direct sale of 18,334 shares in August 2025, suggesting a recurring pattern of trimming director grants back to a consistent floor of roughly 25,000 shares.What does the transaction value signal about the market environment for Sharplink?
The shares were sold at around $7.41 per share, above the post-transaction close of $7.17 on May 12, 2026, during a period when the stock had delivered a 116.6% one-year total return as of the trade date.Company overviewMetricValueRevenue (TTM)$39.4 millionNet income (TTM)($1.4 billion)Price (as of market close June 12, 2026)$5.51* 1-year performance is calculated using June 12, 2026 as the reference date.
Company snapshotSharplink operates an institutional-grade Ethereum treasury platform and provides affiliate marketing services for sportsbook and online casino gaming operators.The company generates revenue through ETH treasury management, including staking and risk-managed custody, as well as performance-based customer acquisition for gaming clients.Primary customers include licensed gaming operators in the U.S. and internationally, as well as institutional clients seeking ETH treasury solutions.Sharplink leverages its dual-segment strategy to address both the digital asset management and gaming affiliate marketing sectors. The company’s ETH treasury management platform is designed for institutional clients, providing staking and governance solutions within a robust risk management framework. Its affiliate marketing network supports gaming operators by driving user acquisition and engagement, positioning Sharplink as a diversified player in digital finance and online gaming services.
What this transaction means for investorsSharplink is essentially a bet on Ethereum. The gaming affiliate business is still there, but the company's identity — and nearly all of its Q1 2026 revenue — now runs through its ETH treasury and staking operations. That pivot is working on the top line: revenue jumped to $12.1 million in Q1 2026 from $0.7 million a year earlier, driven by ETH staking. The bull case is straightforward — Sharplink is accumulating ETH, generating yield on it, and expanding into DeFi through a new Galaxy Digital partnership. If you believe Ethereum has a durable role in institutional finance, the accumulation strategy makes sense. The bear case is just as clear: the company posted a net loss of $685.6 million in Q1, largely from a $506.7 million unrealized loss on crypto assets and a $191.7 million impairment on liquid staking tokens. Those are non-cash GAAP charges, not ETH leaving the treasury, but they signal how much volatility investors are absorbing. McKenzie's sale is a one-paragraph footnote to all of this — a director trimming a comp grant after a strong run. The real question is whether you want ETH exposure through a corporate treasury wrapper, with the added operational and accounting complexity that comes with it, or whether you'd rather own ETH directly. If you're still building your view on the space, check out our article on how to build a crypto portfolio.
Seena Hassouna has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
Analysts are Bullish on the Micron StockMicron has become one of the best-performing companies in Wall Street. It has jumped by 232% this year, making it the second-best performing company in the S&P 500 Index after Sandisk (NASDAQ:SNDK).
Micron has soared by over 1,100% in the last 12 months, with its market capitalization crossing the $1 trillion mark.
Wall Street analysts are bullish on Micron, citing its large and growing addressable market and the ongoing DRAM shortage. Benzinga data shows that most pros have boosted their targets for the stock.
Wolfe Research's Chris Caso hiked his target from $550 to $1,250, while Wells Fargo's Aaron Rakers hiked from $550 to $1,220. Cantor Fitzgerald hiked to $1,500, while Morgan Stanley's Joseph Moore hiked to $1,050.
Most of these analysts boosted their outlooks after the company published its strong financial results. The most recent numbers showed that its revenue surged by 75% QoQ and 196% YoY to $23 billion. Most of this growth was because of its DRAM business, which made $18.8 billion.
Analysts are optimistic that the growth will continue as the AI boom continues. The average estimate is that the annual revenue will jump by 200% to $111 billion, followed by $183 billion next year.
Valuation Multiples Show That MU Stock Has More UpsideDespite the ongoing surge in Micron's stock, there are signs that the company may still be undervalued, which could support further gains.
According to FactSet (NYSE:FDS), the S&P 500 Index has a forward PE ratio of 21. As such, a fast-growing company like Micron should have a higher multiple than that.
The same is true for other valuation multiples. Its forward price-to-earnings-to-growth ratio has dropped to just 0.11, lower than the sector median of 1.43. PEG ratio is often seen as a better metric than PE because it takes into account of a company's growth.
Micron's rule-of-40 metric is also one of the best in the US. It has a forward revenue growth of 198% and a net profit margin of 42%, giving it a metric of 240%.
Still, despite these numbers, the main risk the company faces is a reversal in the memory industry. With the prices rising, there is a risk that companies will boost their production, which may lead to an oversupply in the future.
Image: Shutterstock
Market News and Data brought to you by Benzinga APIs
SpaceX (NASDAQ:SPCX) stock price jumped by 19% on its first day as a publicly-traded company, with its valuation crossing the $2 trillion mark as most analysts were expecting.
Analysts Have Mixed Opinions on SpaceX StockJim Chanos, the famed short-seller who blew the whistle on Enron, warned that the elevated valuation made no sense. He pointed to its losses and its 2025 revenue of $18 billion.
Why SPCX Stock May Drop After the IPOThere are several reasons why the SpaceX stock will retreat in the coming weeks or months. First, the hype surrounding its IPO will fade as investors embrace the new normal and start focusing on the upcoming OpenAI and Anthropic IPOs.
Further, the company is losing billions of dollars because of its AI business, which it gained by merging with xAI. Its most recent results showed that it suffered a net loss of over $4.2 billion in the first quarter of this year. It suffered a $4.9 billion last year.
The other reason it may drop is that its tiered lock-up expiry will happen after 180 days. This expiration makes it possible for insiders to start selling their shares. In most cases, stocks often retreat ahead of the expiration date.
Image: Shutterstock
Market News and Data brought to you by Benzinga APIs
SpaceX (NASDAQ:SPCX) stock price jumped by 19% on its first day as a publicly-traded company, with its valuation crossing the $2 trillion mark as most analysts were expecting.
Analysts Have Mixed Opinions on SpaceX StockJim Chanos, the famed short-seller who blew the whistle on Enron, warned that the elevated valuation made no sense. He pointed to its losses and its 2025 revenue of $18 billion.
Why SPCX Stock May Drop After the IPOThere are several reasons why the SpaceX stock will retreat in the coming weeks or months. First, the hype surrounding its IPO will fade as investors embrace the new normal and start focusing on the upcoming OpenAI and Anthropic IPOs.
Further, the company is losing billions of dollars because of its AI business, which it gained by merging with xAI. Its most recent results showed that it suffered a net loss of over $4.2 billion in the first quarter of this year. It suffered a $4.9 billion last year.
The other reason it may drop is that its tiered lock-up expiry will happen after 180 days. This expiration makes it possible for insiders to start selling their shares. In most cases, stocks often retreat ahead of the expiration date.
Image: Shutterstock
Market News and Data brought to you by Benzinga APIs
The artificial intelligence boom has created a familiar pattern on Wall Street. Investors spend years chasing the market's biggest winner, then spend the next few years searching for whatever comes next. That search is happening right now with Nvidia (NASDAQ: NVDA). After becoming one of the most successful investments in stock market history, Nvidia's recent performance... Should You Look for the "Next Nvidia" - or Just Buy the Real Thing?
BEERSE, BELGIUM, June 13, 2026 (GLOBE NEWSWIRE) -- Johnson & Johnson today announced results from the investigational Phase 3 MonumenTAL-3 study.1 The results showed that TALVEY® (talquetamab), a GPRC5D bispecific antibody, in combination with daratumumab with or without pomalidomide demonstrated significant reduction in the risk of disease progression or death of up to 72.0%, and clinically meaningful reduction of up to 53.0% in the risk of death, compared to the standard regimen of daratumumab, pomalidomide, and dexamethasone (DPd) in patients with relapsed or refractory multiple myeloma (RRMM).1 Results showed a progression-free survival (PFS) rate of up to 81.3% versus standard of care (51.2%) and an overall survival (OS) rate of up to 89.2% versus standard of care (79.1%) at 24 months.
Anthropic and OpenAI Have Filed Their IPO PapersThe most-watched companies are Anthropic, the creator of Claude, and OpenAI, the creator of ChatGPT. The two have already filed confidential papers for their listings.
OpenAI recently raised funds from companies like Nvidia (NASDAQ:NVDA) and Softbank at a $850 billion valuation. Anthropic also raised cash at a $900 billion valuation.
Polymarket traders predict that these companies will cross $1 trillion valuations after their IPO, thanks to their strong revenue growth and market share in the artificial intelligence industry.
Anthropic has gone viral this year after launching several products, including Mythos and Fable. It also launched tools focusing on key industries, raising concerns about the software industry. Its second-quarter revenue is expected to more than double to over $10 billion. It is also expected to turn a profit.
AndurilAnduril is a top company at the intersection of artificial intelligence and the defense industry. It has already raised over $11.6 billion from venture capital firms. Its most recent fundraising of $5 billion came from Thrive Global and Andresseen Horowitz. It valued it at over $61 billion.
Anduril has not confirmed when it will go public, but analysts expect that it will happen in the next few years. The company is benefiting from the ongoing defense spending surge, with President Trump asking Congress for $1.5 trillion.
Also, the company has invested in drone technology, which has become useful during the US-Iran war. It has recently received major orders, including a $20 billion one from the US Army and is a major part of Trump's Golden Dome project.
DatabricksWhile Databricks is not a household name, it is a popular company among corporates. It is a top Oracle (NASDAQ:ORCL) competitor that runs a data warehouse platform.
StripeStripe has not confirmed when it will go public. However, for a company that was established in 2010 and one that has raised funds from venture capitalists, chances are that it will have to go public soon.
Some of the other tech companies that may launch their IPOs soon are Blue Origin, Figure AI, Revolut, and Kraken. Kraken has already launched its papers, with the only limiting factor being the ongoing crypto winter.
Source: Shutterstock
Market News and Data brought to you by Benzinga APIs
Passive income arrives while you sleep, commute, or vacation. That appeal drives dividend investing: a paycheck every quarter regardless of market conditions or work hours.
Layoff announcements have rattled white-collar industries through the first half of 2026, and essentials costs climb faster than most household raises. Building a cash-flowing portfolio is one of the few defenses an individual investor controls directly. Unlike rental real estate, a high-yield dividend portfolio is liquid, requires no tenant management, and lets you redirect capital with a single trade.
We screened our 24/7 Wall St. dividend equity research database for stocks that pay massive dividends. A collection of companies can generate over $1,900 a year in passive annual income if you invest $10,000 in each stock at the time of this writing.
Verizon Communications Yield: 6.08% Shares for $10,000: 213 Annual Passive Income: $608 Verizon (NYSE:VZ | VZ Price Prediction) is the largest U.S. wireless carrier and fiber broadband powerhouse following the January 20, 2026 close of the Frontier Communications acquisition, which expanded its fiber footprint to more than 30 million homes and businesses.
The dividend is fueled by predictable subscriber cash flow: FY 2025 operating cash flow of $37.1 billion covered $11.5 billion in common dividends with a 1.75x cushion.
Telecom is a regulated, capital-heavy industry where mature operators return excess cash through dividends rather than reinvest for hypergrowth. Verizon raised its quarterly payout to $0.7075 per share in 2026, extending annual increases spanning over two decades. Management completed $2.5 billion in buybacks in Q1 2026 while paying down Frontier-related debt.
Pfizer Yield: 6.61% Shares for $10,000: 390 Annual Passive Income: $661 Pfizer (NYSE:PFE) is a global biopharmaceutical company spanning Primary Care, Specialty Care, and Oncology, with blockbuster brands including Eliquis, Prevnar, Vyndaqel, Ibrance, Padcev, and Nurtec ODT.
The high yield reflects post-COVID revenue normalization rather than business distress: FY 2025 operating cash flow of $11.7 billion covered $9.8 billion in dividends, and management reaffirmed FY 2026 guidance for adjusted EPS of $2.80 to $3.
Big Pharma pays large dividends because mature drug franchises throw off enormous free cash flow exceeding reinvestment needs. Pfizer has raised the payout for 16 consecutive years, moving the quarterly dividend from $0.32 in 2017 to $0.43 in 2026.
A Vyndamax patent settlement extends U.S. exclusivity to June 2031, and the roughly $7 billion Metsera acquisition plants a stake in the obesity drug market. Institutional ownership sits at 69.4%.
Kraft Heinz Yield: 7.09% Shares for $10,000: 415 Annual Passive Income: $709 Kraft Heinz (NASDAQ:KHC) owns Heinz, Kraft, Philadelphia, Primal Kitchen, Lunchables, and Ore-Ida, selling packaged food across North America, International Developed Markets, and Emerging Markets.
The yield is elevated because the share price has compressed: KHC trades down 29.17% over the past five years as volume softness in coffee, cold cuts, and frozen meals weighed on the multiple.
The dividend has held at $0.40 per quarter since 2019 and is well covered by cash: FY 2025 operating cash flow of $4.46 billion against a $1.9 billion payout works out to 2.35x coverage.
New CEO Steve Cahillane paused the previously announced company split and committed $600 million in incremental marketing and R&D investment. Berkshire Hathaway remains the anchor institutional holder, with insiders owning 27.78% of shares.
The Combined Income Picture Combined, these 3 positions generate $1,978 in annual passive income on a $30,000 investment, a blended yield of 6.59%. Kraft Heinz contributes $709, Pfizer adds $661, and Verizon rounds out the portfolio with $608.
Ticker Investment Yield Annual Income Share of Total KHC $10,000 7.09% $709 35.8% PFE $10,000 6.61% $661 33.4% VZ $10,000 6.08% $608 30.7% Total $30,000 6.59% $1,978 100% Reinvested at the same blended yield, that $1,978 would buy roughly another $130 of annual income next year, then another $138 the year after. Cash flow arriving on a schedule lets a portfolio compound without forcing the investor to time entries, exits, or earnings reactions.
A 64-year-old software executive walks out of the office on her last day with $1.6 million sitting in a single employer stock. Her cost basis is $240,000, meaning roughly $1.36 million is embedded long-term capital gain waiting to be triggered. She has no W-2 income starting next January, a paid-off house, and a 401(k) she... 64-Year-Old Tech Exec Holds $1.6 Million in One Stock. The Wrong Move Could Cost $400,000.
Roper Technologies is a diversified software conglomerate with a 33-year dividend growth streak, now trading below historical valuation averages. ROP's aggressive M&A strategy has driven growth but resulted in rising debt and leverage, now at 3.1x, raising concerns about financial flexibility. Despite strong Q1 2026 results and conservative dividend safety metrics, investor fears of AI disruption and increased private equity competition weigh on sentiment.
Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.
CBIZ, Inc. shares have rebounded from 10-year lows after a sharp decline driven by AI disruption fears and increased leverage from acquisitions. With no common dividend, CBZ could potentially repay all debt in about six years using $270-$290 million in annual free cash flow. Unusual underlying value and the prospect of deleveraging have positioned CBZ for a higher equity quote over time.
Analyst’s Disclosure: I/we have a beneficial long position in the shares of KLAR either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.
Coca-Cola (KO +0.11%), the world's largest beverage company, is a reliable blue chip stock. Including reinvested dividends, it delivered a total return of 659% over the past 30 years. Let's see why it's still a great stock to buy today to generate passive income for life.
Why is Coca-Cola an evergreen investment? Over the past few decades, Coca-Cola has expanded its beverage portfolio with more brands of bottled water, fruit juices, teas, sports drinks, energy drinks, dairy products, coffee, and even alcoholic beverages. It also refreshed its flagship sodas with smaller serving sizes, new flavors, and healthier versions. That ongoing expansion and evolution enabled the company to continue growing, even as soda consumption rates fell worldwide.
Image source: Coca-Cola.
Coca-Cola only produces the concentrates and syrups for those beverages, then sells them to independent bottlers, restaurants, and other businesses that produce the finished drinks. That asset-light business model enables it to maintain high operating margins while generating stable cash flow and earnings, even amid economic downturns or choppy macro headwinds. It also doesn't own a struggling packaged foods segment like PepsiCo (PEP +0.35%).
That's also why Coca-Cola raised its dividend annually for 64 consecutive years. That makes it an elite Dividend King, having hiked its payout for at least 50 consecutive years. It currently pays a forward dividend yield of 2.6%. That yield might not seem impressive when the 10-Year Treasury still pays 4.5%, but it will attract more attention as interest rates decline.
Today's Change
(
0.11
%) $
0.09
Current Price
$
82.62
From 2025 to 2028, analysts expect Coca-Cola's EPS to grow at 6.5% CAGR. That growth will be driven by its AI-powered inventory optimization strategies, the ongoing consolidation of its bottling network, as well as its stronger sales of dairy, energy, and sugar-free drinks. Its bottling partners will also continue to sell a higher mix of smaller, higher-margin cans.
Why is Coca-Cola a good stock to buy in June? At $83, Coca-Cola's stock still looks reasonably valued at 25 times its trailing earnings. By comparison, the S&P 500 looks historically expensive at 32 times earnings. Rising inflation, the Middle East conflict, and other macro headwinds could deflate those valuations in the second half of 2026.
If that market pullback happens, more investors will rotate toward safe-haven stocks like Coca-Cola. Therefore, it seems to be a great time to buy more shares of Coca-Cola -- and commit to holding them for decades -- to earn a lifetime of reliable dividends.
LOS ANGELES--(BUSINESS WIRE)--The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Microsoft Corporation (“Microsoft” or “the Company”) (NASDAQ: MSFT) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Investors who purchased the Company’s securities between May 1, 2025 and January 28, 2026, inclusive (the “Class Period”), are encouraged to contact the firm before August 11, 2026.
If you are a shareholder who suffered a loss, click here to participate.
We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at [email protected].
The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.
According to the Complaint, the Company made false and misleading statements to the market. Microsoft’s Copilot AI products suffered from problems ranging from poor user experience to capacity limitations. The Company’s AI model ranked poorly against competitors on industry benchmark tests. The Company would need to spend billions on capital expenditures related to AI including diverting hardware away from profitable business units to improve its competitive posture in artificial intelligence. The Company was incapable of converting a large percentage of Microsoft 365 users to paid Copilot subscriptions, losing market share to rivals. Based on these facts, the Company’s public statements were false and materially misleading throughout the class period. When the market learned the truth about Microsoft, investors suffered damages.
Join the case to recover your losses
The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
Few companies have ever defined a technology shift the way Nvidia (NVDA +0.15%) has defined the rise of artificial intelligence (AI). Its chips sit at the center of nearly every major AI project, and the stock has been one of the market's best performers over the past few years. A run like that keeps one question permanently in the air: at nearly $5 trillion in market value, is there still room for the stock to climb?
There is a great contrast between Nvidia's business momentum and the stock's recent performance. The chipmaker reported another quarter of accelerating growth last month, yet the growth stock sits about 13% below its all-time high and has gone largely sideways for months, even as the broader market climbed.
Is this a buying opportunity?
Image source: Getty Images.
Demand keeps accelerating Nvidia's fiscal first quarter of 2027 (the period ended April 26, 2026) was, by almost any measure, a standout. Revenue rose 85% year over year to $81.6 billion -- faster than the 73% growth of the prior quarter and the 62% before it, an unusual acceleration for a company this large.
Behind that figure is the data center business, where Nvidia's AI chips live. Data center revenue jumped 92% year over year to $75.2 billion, more than 90% of the company's total sales.
And management sounds confident the demand will hold. On the company's fiscal first-quarter earnings call, it pointed to about $1 trillion of revenue from its current Blackwell and next-generation Rubin chips between 2025 and the end of 2027 -- up from about $500 billion a year earlier. Guidance backs this up. Nvidia expects fiscal second-quarter revenue of about $91 billion, and that outlook assumes no data center compute revenue from China.
"Demand has gone parabolic. The reason is simple. Agentic AI has arrived," said Nvidia founder and CEO Jensen Huang during the company's fiscal first-quarter earnings call.
Those sales also carry remarkable margins. Nvidia's gross margin sat near 75% last quarter, and the company returned about $20 billion to shareholders while authorizing another $80 billion in share repurchases. And much of its hardware runs on Nvidia's own software, which developers have spent years building around -- making the company hard to replace even when rivals match its chips.
Today's Change
(
0.15
%) $
0.30
Current Price
$
205.18
What could go wrong But even a great business can turn into a mediocre investment if too much optimism is already baked into the price.
So is Nvidia's valuation reasonable?
Nvidia trades at a price-to-earnings ratio of about 31 -- a premium to the broader market, though hardly extreme for a company growing this fast.
But there are risks that help explain the stock's seemingly conservative valuation.
China is one overhang. The country once made up at least a fifth of Nvidia's data center revenue, and management's outlook now assumes zero revenue from the important market -- a reminder of how quickly geopolitics can close off a major market.
Then there's the awkward fact that some of Nvidia's biggest customers are also its potential rivals. The large cloud providers buying its chips are designing their own at the same time, and if enough of them build future systems without Nvidia's hardware inside, Nvidia's pricing power could weaken over time. And pureplay chip competitors like AMD (AMD +4.91%) are pressing with their own AI accelerators, too.
So, is Nvidia stock a buy?
For investors with a long-term time horizon, I think the stock looks attractive here. The business is exceptional, and the valuation looks attractive relative to the company's recent growth. Still, there are some serious risks. So, keeping any position in the stock small is probably a good idea.
Thistle Resources (TSX-V:TRCG, OTC:TRCGF) earlier this week reported encouraging drill results from its flagship Middle River Gold project in New Brunswick's Bathurst Mining Camp, with management saying the latest intersection continues to support the scale and growth potential of the emerging gold system.
Speaking with Proactive, chief executive Patrick Cruickshank said drill hole 21TRC-AU007 returned a significant gold-bearing interval from a shallow section of the deposit. The hole formed part of the company's ongoing drilling campaign aimed at expanding and defining mineralisation at Middle River.
Cruickshank reported that the 74-metre drill hole intersected 21 metres of significant gold mineralisation at a composite grade of approximately 1.66 g/t gold. He described the result as "a pretty rich composite over 74m" and noted that it also contained stronger intervals over eight metres and 14 metres.
The CEO said the result further validates the company's exploration model. Thistle has identified seven kilometres of mineralised folds across the project area through geophysical work undertaken with specialist partners. To date, the company has defined a deposit extending roughly 400 metres along one of those folds.
A key catalyst for investors will be the company's continued drilling program. Cruickshank explained that Thistle intends to focus on expanding the current mineralized trend before progressing to additional targets. The strategy is designed to support future inferred and indicated resource estimates through systematic step-out drilling and improved drill density.
The broader exploration opportunity remains significant. Management has identified approximately 50 target centres across the seven-kilometre trend, with each target potentially requiring multiple drill holes. According to Cruickshank, the scale of the mineralized system could support a resource substantially larger than the company's current objective.
He stated that the initial goal is to define more than two million ounces of gold, but suggested the figure may ultimately prove conservative if exploration success continues. Cruickshank said the mineralised fold system has so far performed in line with expectations and has yet to produce a significant miss.
Alongside Middle River, another important catalyst is the advancement of the Brunswick Antimony project. Cruickshank said the company plans to begin drone surveys and trenching activities immediately. The asset hosts gold, silver and high-grade antimony mineralization, including antimony grades exceeding 10%.
Oracle's (ORCL 0.05%) stock is getting pummeled after reporting its fourth-quarter and full-year fiscal 2026 earnings. Shares fell more than 12% after the software giant disclosed its plans to raise $40 billion through debt and equity financing. Only $20 billion of that raise had been previously announced. Oracle's free cash flow is negative for the fiscal year, with a cash burn of $23.7 billion.
The question for investors is whether Wall Street's expectations for tech companies have become untenable, or if this is a red flag for Oracle shareholders.
Today's Change
(
-0.05
%) $
-0.10
Current Price
$
184.00
The report wasn't bad in any sense. The tech company had record earnings per share, total revenues, and remaining performance obligations for Q4 2026. For the full fiscal year, it was a banner period, with revenues reaching $67.4 billion, a 17% increase. Earnings per share (EPS) were also up 34% to $5.83.
Oracle's outlook for fiscal 2027 is also strong, as the company raised its EPS guidance to $8.05. It also reaffirmed revenue expectations at $90 billion.
Image source: The Motley Fool.
To make money, you have to spend money, as the adage goes, and Oracle is doing a lot of that. Capital expenditures exceeded company guidance, and this, along with the additional $40 billion cash commitment for 2027, is what spooked investors.
Still, with an enormous backlog of business, the steep, rapid decline in the stock price feels like an overreaction. It is also similar to what happened with Broadcom (AVGO 0.85%) recently. Broadcom's quarterly earnings were strong but fell short of the extraordinarily high bar set by Wall Street analysts. The stock fell precipitously.
For buy-and-hold investors, Oracle's fundamentals remain intact. The sell-off is more of an opportunity than a warning flag.
Catie Hogan has positions in Oracle. The Motley Fool has positions in and recommends Broadcom and Oracle. The Motley Fool has a disclosure policy.
